{"title": "Aurora A and AKT Kinase Signaling Associated with Primary Cilia", "pubDate": "2021", "PMCID": "PMC8699881", "DOI": "10.3390/cells10123602", "PMID": "34944109", "abstract": "Dysregulation of kinase signaling is associated with various pathological conditions, including cancer, inflammation, and autoimmunity; consequently, the kinases involved have become major therapeutic targets. While kinase signaling pathways play crucial roles in multiple cellular processes, the precise manner in which their dysregulation contributes to disease is dependent on the context; for example, the cell/tissue type or subcellular localization of the kinase or substrate. Thus, context-selective targeting of dysregulated kinases may serve to increase the therapeutic specificity while reducing off-target adverse effects. Primary cilia are antenna-like structures that extend from the plasma membrane and function by detecting extracellular cues and transducing signals into the cell. Cilia formation and signaling are dynamically regulated through context-dependent mechanisms; as such, dysregulation of primary cilia contributes to disease in a variety of ways. Here, we review the involvement of primary cilia-associated signaling through aurora A and AKT kinases with respect to cancer, obesity, and other ciliopathies.", "author": [{"author": "Yuhei Nishimura", "affiliation": ["Department of Integrative Pharmacology, Graduate School of Medicine, Mie University, Tsu 514-8507, Japan.", "Glocal Research Center for Advanced Medical Science, Mie University, Tsu 514-8507, Japan."], "href": "/?term=Nishimura+Y&cauthor_id=34944109"}, {"author": "Daishi Yamakawa", "affiliation": ["Department of Physiology, Graduate School of Medicine, Mie University, Tsu 514-8507, Japan."], "href": "/?term=Yamakawa+D&cauthor_id=34944109"}, {"author": "Takashi Shiromizu", "affiliation": ["Department of Integrative Pharmacology, Graduate School of Medicine, Mie University, Tsu 514-8507, Japan."], "href": "/?term=Shiromizu+T&cauthor_id=34944109"}, {"author": "Masaki Inagaki", "affiliation": ["Glocal Research Center for Advanced Medical Science, Mie University, Tsu 514-8507, Japan.", "Department of Physiology, Graduate School of Medicine, Mie University, Tsu 514-8507, Japan."], "href": "/?term=Inagaki+M&cauthor_id=34944109"}], "refPMID": ["25630872", "11589691", "14960716", "26745528", "32989298", "32453400", "30250494", "32439931", "29465396", "23729733", "27339427", "28342286", "29946042", "30518564", "19111882", "6719137", "27050099", "23792191", "25175806", "29632185", "31131274", "28202658", "31562563", "28732278", "32219470", "33995085", "34169630", "30733609", "27634431", "23475109", "26719793", "27669693", "30643718", "34420822", "29689227", "29548942", "30224385", "31611503", "28624967", "30064990", "30213760", "33107052", "476831", "229969", "480410", "17604723", "22529102", "25270598", "26880200", "29472535", "30864703", "32357862", "25180231", "23370327", "28625917", "19147554", "28028031", "16775032", "18660794", "23369289", "25313256", "19047091", "23351307", "20530462", "23844214", "32156598", "22096570", "30008323", "23246966", "28586053", "29802351", "30884815", "30867732", "32825105", "32169416", "33051411", "27323230", "31761534", "33691104", "24667636", "19759305", "18316029", "17825558", "25543293", "29311635", "29311636", "29311637", "18454148", "30948523", "19190184", "22958920", "32970140", "29874589", "31412932", "26636082", "28127048", "22864622", "22472437", "21723128", "16890155", "13678582", "21147853", "16332542", "18345035", "22621899", "22609948", "12631597", "21113414", "30302130", "15731013", "21325031", "31893523", "20643351", "29401581", "11163259", "11163260", "16184168", "23539442", "20842194", "27653015", "27756681", "25967390", "25139996", "20451172", "26195043", "29298421", "14520415", "30446775", "28264986", "28295209", "30622327", "33475699", "27471559", "29434995", "31715259", "28431241", "17450132", "25435019", "21873248", "31846650", "25637533", "32466971", "19596798", "25693948", "29243339", "28709001", "12538586", "19433058", "32302547", "28356571", "33248874", "16645198", "21628426", "31573840", "32999001", "26807644", "15951036", "26163824", "24709879", "29457544", "25465296", "33715811", "34428960", "19276629", "10637311", "26159735", "33692993", "32205411", "31862695", "33816471", "31997226", "26701933", "22819197", "32850869", "26862211", "19668216", "27056978", "27401686", "28031327", "11292862", "11595184", "12050673", "25533676", "26564077", "16849532", "27563096", "32603638", "34002003", "23797736", "24487277", "29651023", "26233890", "34002056", "29045126", "28807782", "29908451", "12177045", "18663142", "33839740", "34183730", "32968059", "27885283", "31200857", "34249939", "30838853", "32082969", "26101564", "31859249", "26880702", "18513937", "31931101", "32559187", "34025443", "27624869", "24212374", "29740315", "31142652", "26029358", "16908183", "27003291", "32503249", "33130249", "28110720", "29358593"], "citedInPMID": ["34944109"], "body": " AbstractDysregulation of kinase signaling is associated with various pathological conditions, including cancer, inflammation, and autoimmunity; consequently, the kinases involved have become major therapeutic targets. While kinase signaling pathways play crucial roles in multiple cellular processes, the precise manner in which their dysregulation contributes to disease is dependent on the context; for example, the cell/tissue type or subcellular localization of the kinase or substrate. Thus, context-selective targeting of dysregulated kinases may serve to increase the therapeutic specificity while reducing off-target adverse effects. Primary cilia are antenna-like structures that extend from the plasma membrane and function by detecting extracellular cues and transducing signals into the cell. Cilia formation and signaling are dynamically regulated through context-dependent mechanisms; as such, dysregulation of primary cilia contributes to disease in a variety of ways. Here, we review the involvement of primary cilia-associated signaling through aurora A and AKT kinases with respect to cancer, obesity, and other ciliopathies. Keywords: primary cilium, aurora kinase A, AKT kinase, trichoplein, lipid raft, proliferation, differentiation, cancer, obesity, ciliopathy 1. IntroductionThe human genome encodes 538 protein kinases [1] that play crucial roles in cellular homeostasis through both catalytic and noncatalytic mechanisms [2,3]. Kinase activity is subject to environmental and spatiotemporal regulation, and the consequences of protein phosphorylation are thus affected not only by the particular protein substrate but also by the cellular and subcellular context [4,5,6]. Therapeutic targeting of kinases most often focuses on their catalytic activity, but their noncatalytic functions are also essential to cellular homeostasis and are of increasing therapeutic interest. This is particularly true for the main focuses of this review: the serine/threonine kinases aurora kinase A (AURKA) and v-akt murine thymoma viral oncogene homolog (AKT) [4,5,6,7,8].AURKA, which is itself regulated by phosphorylation and dephosphorylation, plays an essential role in mitosis through its noncatalytic function as a binding partner for several key regulatory proteins. Not surprisingly, dysregulation of this AURKA noncatalytic function is known to contribute to the development and progression of various diseases, including cancer and obesity. One example is the interaction between AURKA and microtubule nucleation factor targeting protein for xenopus kinesin-like protein 2 (TPX2) during mitosis [9]. In melanoma cells, a mutation in a key AURKA-inactivating phosphatase results in aberrant AURKA activation and its sustained interaction with TPX2 [10]. Inhibition of the AURKA\u2013TPX2 interaction has thus been proposed as a novel therapeutic approach for melanoma with minimal effects on the proliferation of normal cells [11,12,13,14]. AURKA also acts as a scaffold protein and stabilizes the oncogenic transcription factor v-myc avian myelocytomatosis viral oncogene neuroblastoma-derived homolog (MYCN) by interfering with its degradation [15]. MYCN is amplified in some forms of neuroblastoma and prostate cancers and predicts poor prognosis [16,17]; therefore, inhibition of AURKA\u2013MYCN binding might also be a useful therapeutic approach in these cancers [13,18,19].Another clinically important kinase with crucial catalytic and noncatalytic functions is AKT. AKT lies at the crossroads of many interconnecting pathways with functions in cell metabolism, proliferation, differentiation, and survival. In addition, the conformation, but not the catalytic activity, of the AKT kinase domain plays a role in controlling the ability of the adjacent pleckstrin homology (PH) domain to bind membrane-associated lipids [20]. Thus, both catalytic and noncatalytic activities play a role in AKT function [6,21] and, similar to AURKA, AKT dysregulation plays a role in many major disorders, including cardiovascular and metabolic diseases and cancer. Taken together, these observations suggest that therapeutic approaches that specifically target kinase catalytic and noncatalytic functions in a context-dependent manner could not only improve efficacy but also minimize potential adverse effects [21,22,23,24,25,26,27].Primary cilia are nonmotile, 1\u201310 \u03bcm long antenna-like structures that extend externally from the plasma membrane of a variety of vertebrate cells [28,29,30,31,32,33,34]. The cilium contains a scaffold of microtubules, the axoneme, that transports molecules into and out of the ciliary body through a process known as intraflagellar transport. The axoneme is anchored to the plasma membrane via a basal body that is derived from the mother centriole containing nine circularly arranged triplets of microtubules [29]. Primary cilia contain receptors and channels that detect signals from the extracellular milieu, such as chemical stimulation and mechanical flow, and transduce them into the cell to regulate physiological functions [28,29,30,31,32,33,34,35,36,37,38].Although primary cilia are nonmotile, cilia formation is dynamically regulated in response to various stimuli [29,30,31,32,33,34,37,38,39,40,41,42]. For example, primary cilia in serum-deprived fibroblasts and retinal pigment epithelial (RPE) cells undergo disassembly upon addition of serum [43,44,45,46]. Furthermore, forced ciliation has been shown to disrupt progression of the cell cycle in proliferating human RPE cells [47,48,49,50], illustrating the importance of these organelles for proper cell function. The abundance of primary cilia is reduced in a range of cancer types, including glioblastoma [51], esophageal squamous cell carcinoma [52], colon cancer [53], cholangiocarcinoma [54,55], pancreatic ductal adenocarcinoma [56,57], clear cell renal cell carcinoma [58,59,60,61], epithelial ovarian cancer [62,63], luminally derived breast cancer [64], prostate cancer [65,66], melanoma [67,68], and chondrosarcoma [69,70], highlighting the importance of negative regulation of the cell cycle and proliferation by primary cilia [30,31,32,33,71,72,73,74,75,76].In addition to cancer, dysregulation of primary cilia is associated with obesity [77,78,79]. The arcuate nucleus of the hypothalamus is composed of different types of ciliated neurons, including anorexigenic and orexigenic neurons, which express leptin receptors in the primary cilia [80]. Upon binding of leptin to the receptors, production of anorexigenic and orexigenic neuropeptides is increased and decreased, respectively, leading to appetite suppression [81,82]. Accordingly, loss of primary cilia in these neurons impairs the negative-feedback system crucial to controlling appetite [83,84]. Anorexigenic and orexigenic neuronal axons project into second-order neurons in the paraventricular nucleus that express melanocortin 4 receptor (MC4R), a common receptor for anorexigenic and orexigenic neuropeptides, and adenylate cyclase 3 (ADCY3) in the primary cilia [85]. Mutations in MC4R and ADCY3 have been associated with an increased risk of obesity and Type 2 diabetes [86,87,88]. Increased adipogenesis is another important cause of obesity [89]. For example, knockdown of the causative genes for Bardet\u2013Biedl syndrome (BBS), a ciliopathy inherited in an autosomal-recessive manner, suppresses the formation of primary cilia in preadipocytes and increases adipogenesis through activation of peroxisome proliferator activated receptor \u03b3, a master regulator of adipogenesis [90,91].These examples serve to illustrate how breakdown in the normal physiological regulation of cilia dynamics and signal transduction can contribute to human diseases [28,33,34,92] and further highlight the role of numerous kinases in regulating primary cilia function [63,93,94]. In the remainder of this review, we focus on the association between AURKA (Section 2) and AKT (Section 3) and primary cilia function and how their dysregulation contributes to ciliopathies such as cancer and obesity (Figure 1).Open in a separate windowFigure 1Overview of the involvement of AURKA and AKT associated with primary cilia in cellular functions. AURKA and AKT located at the ciliary base mediate signaling from extracellular stimuli that regulate crucial cellular functions, including proliferation, differentiation, and metabolism. Among other functions, AURKA and AKT signaling regulates the assembly and disassembly of primary cilia and the dynamics of signaling hubs known as lipid rafts, which are located in the plasma membrane around primary cilia. Dysregulation of these functions contributes to a number of ciliopathies, including cancer and obesity, as described in this review. 2. Aurora Kinase a Signaling and Its Regulation in Primary CiliaAURKA is a member of the aurora kinase family that play essential roles in regulation of the cell cycle [7,95,96,97,98]. During mitosis, AURKA is activated by autophosphorylation in a manner dependent on its interaction with distinct proteins at different stages of the mitotic process: polo-like kinase 1 (PLK1) and protein aurora borealis at G2/M [99,100], Ajuba LIM protein at prophase [101], and TPX2 at metaphase [102]. Activated AURKA stimulates mitotic entry and centrosome separation and maturation at G2/M [99,100], formation of the microtubule-organizing center, mitotic spindle organization, and chromosome alignment at M phase [103,104]. AURKA also plays important roles during G1 through promoting the disassembly of primary cilia [22,23,30,31,32,33,38,46,47,48,49,50,71,105,106]. Notably, formation of primary cilia is suppressed in several cancers in which expression of AURKA is increased, including epithelial ovarian cancer [63], prostate cancer [66], pancreatic ductal adenocarcinoma [57,107], and glioblastoma [108,109]. These findings suggest that inhibition of AURKA may suppress the proliferation of these cancer cells by promoting ciliogenesis [22,30,31,32,33,34,38,71,74]. Various proteins have been identified as modulators of AURKA-mediated disassembly of primary cilia during G1, including trichoplein (TCHP), neural precursor cell expressed developmentally downregulated 9 (NEDD9), and centrosomal protein 55 (CEP55), which we discuss in more detail here (Figure 2).Open in a separate windowFigure 2AURKA signaling associated with primary cilia. (A) Regulation of AURKA through TCHP. In the presence of growth factors (left panel), USP8 is activated by RTK-mediated phosphorylation, leading to deubiquitination of TCHP, activation of AURKA, and suppression of ciliogenesis. In the absence of growth factor (right panel), USP8 is inactive, and TCHP is degraded via ubiquitination by CRL3-KCTD17. (B) Regulation of AURKA through NEDD9. In the presence of WNT5a (left panel), CK1\u03b5 phosphorylates DVL2, resulting in suppression of NEDD9 ubiquitination through APC10. NEDD9 activates AURKA and suppresses ciliogenesis. In the absence of WNT5a (right panel), NEDD9 is targeted for degradation by APC10-mediated ubiquitination. (C) CEP55 stabilizes AURKA. The CCT5-containing chaperonin CCT complex interacts with wild-type CEP55 and stabilizes AURKA, resulting in suppression of ciliogenesis (left panel). In cells harboring a Cys256Thr mutation in CEP55, which is associated with MARCH, mutant CEP55 fails to localize to the centrosome, leading to destabilization of AURKA and elongation of primary cilia (right panel). Abbreviations: APC10, anaphase-promoting complex subunit 10; CCT5, chaperonin-containing TCP1 subunit 5; CK1\u03b5, casein kinase 1\u03b5; CRL3-KCTD17, E3 ligase complex composed of cullin 3, ring-box 1, and potassium channel tetramerization domain\u2013containing 17; Cys, cysteine; DVL2, disheveled segment polarity protein 2; MARCH, multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly; PLK1, polo-like kinase 1; RTK, receptor tyrosine kinase; SMAD3, SMAD family member 3; Thr, threonine; Ub, ubiquitin; USP8, ubiquitin-specific protease 8; WNT5a, Wnt family member 5A.2.1. TCHPTCHP, originally identified as a keratin-binding protein [110,111], is a centriolar protein that suppresses the formation of primary cilia by directly interacting with AURKA [27,47,48,49,50,79]. The N-terminal 130 residues of TCHP are essential for its centriolar localization, its interaction with AURKA, and its involvement in the suppression of ciliogenesis [47]. Knockdown (KD) of TCHP in human RPE cells cultured in the presence of serum inhibits AURKA activation, induces ciliogenesis, and suppresses cell proliferation [47]; however, the effects on ciliogenesis and proliferation are suppressed by co-KD of intraflagellar transport 20 (IFT20), a protein required for primary cilia assembly [47,112]. These findings clearly demonstrate that ciliogenesis can inhibit the cell cycle and that TCHP\u2013AURKA regulate cell proliferation via their effects on primary cilia [30,31,32,33,34,38,74] (Figure 2A).TCHP expression is regulated by the ubiquitin\u2013proteasome system [48,49,50]. TCHP is ubiquitinated by an E3 ligase complex composed of cullin 3, ring-box 1, and potassium channel tetramerization domain-containing 17 (CRL3KCTD17) [48]. Conversely, deubiquitination of TCHP is mediated by ubiquitin-specific peptidase 8 (USP8) [50]. KD of KCTD17 and USP8 suppresses and promotes, respectively, the formation of primary cilia in human RPE cells [48,50]. In zebrafish, knockout (KO) of kctd17 impairs ciliogenesis in Kupffer\u2019s vesicle and induces situs inversus [74], whereas KO of usp8 increases ciliogenesis in the pronephric duct and causes renal cysts [50]. Dysregulation of AURKA is also associated with situs inversus and polycystic kidney in mice [113,114]. Thus, impairment of the TCHP\u2013AURKA interaction may contribute to the pathophysiology of these disorders.The activity of CRL3KCTD17 in human RPE cells is unaffected by the presence or absence of serum in the culture medium [48], whereas USP8 activity is stimulated by several serum factors, including epidermal growth factor (EGF), platelet-derived growth factor, and fibroblast growth factor, each of which triggers phosphorylation of USP8 at tyrosine (Tyr) 717 and Tyr810 [50]. Activated USP8 stabilizes TCHP by suppressing its proteasomal degradation, which results in activation of AURKA, suppression of ciliogenesis, and stimulation of RPE cell proliferation [50]. KD of the EGF receptor (EGFR) in human RPE cells inhibits USP8 Tyr717 and Tyr810 phosphorylation, which enables TCHP and AURKA degradation and reverses the serum-induced effects on ciliogenesis and cell proliferation [50]. Notably, simultaneous KD of the EGFR and either IFT20 or centrosomal protein 164, both of which are indispensable for ciliogenesis, antagonizes the effects of EGFR KD on ciliogenesis and proliferation [50], supporting the hypothesis that primary cilia act as brakes on cell proliferation [30,31,32,33,34,38,74].NDE1-like 1 (NDEL1), a modulator of dynein activity localized at the subdistal appendage of the mother centriole [115,116], is also involved in TCHP regulation [49]. In human RPE cells, NDEL1 is stabilized in the presence of serum and suppresses CRL3KCTD17-mediated ubiquitination of TCHP, resulting in activation of AURKA [49]. The mechanism of NDEL1 stabilization is unknown but is likely to involve inhibition of degradation, since NDEL1 undergoes proteasomal degradation in the absence of serum [49]. Interestingly, Ndel1-hypomorphic mice display increased ciliation in kidney tubular epithelial cells [49]. Given that usp8 KO in zebrafish also increases ciliation in the pronephric duct [50], these findings suggest that increased degradation of TCHP and subsequent inhibition of AURKA may be involved in the ciliation and cystic kidney defects observed in animals with NDEL1 or USPS8 KD.2.2. NEDD9NEDD9, also known as human enhancer of filamentation 1, is another scaffold protein that affects both AURKA activation and primary cilia formation [46]. Binding of NEDD9 to AURKA, which appears to involve NEDD9 serine (Ser) 296 and the N-terminal domain of AURKA [117,118], suppresses proteasomal degradation of AURKA promoted by the ubiquitin ligase anaphase-promoting complex/C (APC/C) in MDA-MB-231 cells, a human breast cancer cell line [118].NEDD9\u2013AURKA signaling is regulated by several mechanisms (Figure 2B). In primary cilia in human RPE cells, binding of Frizzled receptor to its ligand Wnt family member 5A (WNT5a) stimulates a number of downstream signaling events, including activation of casein kinase 1\u03b5 (CK1\u03b5), which phosphorylates disheveled 2 segment polarity protein 2 (DVL2) and induces formation of a complex with PLK1 and SMAD family member 3 (SMAD3) [106]. The DVL2\u2013PLK1\u2013SMAD3 complex inhibits APC10-induced proteasomal degradation of NEDD9, leading to activation of AURKA signaling and promotion of primary cilia disassembly [106]. Calmodulin also stimulates ciliary disassembly by increasing the interaction between NEDD9 and AURKA [105,119]. In the human esophageal squamous cell carcinoma line EC9760, peroxiredoxin 1, an antioxidant protein frequently overexpressed in tumors [120,121], increases NEDD9 expression and AURKA phosphorylation, resulting in suppression of primary cilia assembly [52]. Hyperactivation of NEDD9\u2013AURKA signaling may thus be involved in oncogenesis through suppression of primary cilia formation [122].Dysregulation of NEDD9\u2013AURKA signaling is involved in several ciliopathy phenotypes. For example, cystogenesis is more extensive in mice with KO of both Nedd9 and polycystin 1 transient receptor potential channel interacting (Pkd1), a causative gene for autosomal dominant polycystic kidney disease, than in mice with KO of Pkd1 alone [123]. The mechanism of elevated cystogenesis in these mice is thought to involve a failure of AURKA activation [123]. Tetratricopeptide repeat domain 8 (TTC8) is involved in formation of primary cilia, and mutation of the TTC8 gene has been associated with nonsyndromic retinitis pigmentosa [124,125,126]. TTC8 is a member of a protein family associated with BBS [127]. A complex composed of TTC8, BBS6, and inversin stimulates ciliogenesis via suppression of NEDD9\u2013AURKA signaling in human RPE cells [128]. Thus, mutation of BBS8 may contribute to the vision impairment associated with retinitis pigmentosa by alleviating the inhibition of NEDD9\u2013AURKA signaling, resulting in suppression of ciliogenesis.2.3. CEP55Mutation of the CEP55 gene is associated with multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly (MARCH), a lethal autosomal-recessive fetal ciliopathy [129,130,131]. CEP55 stabilizes AURKA by facilitating its interaction with a chaperone complex that includes chaperonin-containing TCP1 subunit 5 (CCT5) and promotes the disassembly of primary cilia in human RPE cells [132] (Figure 2C). The C-terminal of CEP55 is critical for both AURKA binding and cilia disassembly [132]. Cep55 KO mice recapitulate many aspects of MARCH, including elongation of primary cilia [132]. These findings suggest that impairment of CEP55\u2013AURKA signaling may play a critical role in the congenital anomalies observed in MARCH.In contrast, evidence suggest that hyperactivation of CEP55\u2013AURKA signaling may be associated with tumorigenesis. CEP55 expression is increased in human glioma tissues and cell lines compared with normal brain tissue and cells [133,134], and high CEP55 expression in glioma is related to poor prognosis [134]. Consistent with this, suppression of CEP55 in human glioma cell lines decreases proliferation [133,134]. Of note, primary cilia are often downregulated in glioblastoma [109]. Given that AURKA has been proposed as a potential therapeutic target in glioblastoma [25], these findings suggest that inhibition of CEP55\u2013AURKA signaling could be a novel strategy for the treatment of glioma and glioblastoma. 3. AKT Signaling and Its Regulation in Primary CiliaThe serine/threonine kinase AKT plays a crucial role in signaling pathways involved in multiple cell functions, including survival, growth, metabolism, proliferation, and differentiation [21]. AKT activation is initiated by engagement of G protein-coupled receptors or receptor tyrosine kinases that are linked intracellularly to class I phosphatidylinositol-3-kinase (PI3K) [21,135]. Activated class I PI3K phosphorylates phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) at the plasma membrane to generate phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3), which then binds to the PH domain of AKT. This interaction recruits AKT to the plasma membrane where it is phosphorylated on threonine (Thr)308 and Ser473 by phosphatidylinositol-dependent protein 1 and mammalian target of rapamycin complex (mTORC) 2, respectively [136]. Dual phosphorylation of AKT at these sites fully activates its enzymatic activity and results in phosphorylation of various key substrates, including B-cell lymphoma-2-associated agonist of cell death, Forkhead box O3, tuberous sclerosis complex 1/2, and glycogen synthase kinase 3\u03b2 (GSK3\u03b2) [135]. These AKT substrates are pivotal regulators of many cellular functions, including protein synthesis, autophagy, proliferation, and differentiation [135,136]. With respect to cilia homeostasis, AKT-mediated phosphorylation of GSK3\u03b2 located at the cilia axoneme suppresses cilia assembly and stability, which contributes to various ciliopathy phenotypes [92,137,138]. The noncatalytic function of AKT is also involved in these activities [6], and AKT activation can occur in a subcellular compartment-specific manner [21,92,135,139,140]. Here, we highlight the regulation of AKT signaling in primary cilia by three mechanisms: by TCHP through altered lipid raft dynamics around primary cilia (Figure 3A), by inositol polyphosphate-5-phosphatase E (INPP5E) (Figure 3B), and by the tumor suppressor von Hippel\u2013Lindau (VHL) protein.Open in a separate windowFigure 3AKT kinase signaling associated with primary cilia. (A) Lipid raft-mediated activation of AKT at the base of primary cilia during adipogenesis. Exposure of preadipocytes to adipogenic stimuli activates IR and IGF1R located at the ciliary base and leads to accumulation of CAV1- or GM3-positive lipid rafts, phosphorylation of AKT, and promotion of adipogenesis. KD or KO of Tchp elongates primary cilia of preadipocytes, which inhibits the accumulation of lipid rafts upon adipogenic stimulation. (B) Regulation of AKT by INPP5E. PI3K and INPP5E balance the generation of PIP3, a key activator of AKT. Loss-of-function mutation in INPP5E increase PIP3, hyperactivates AKT, and suppresses ciliogenesis, leading to cell proliferation, tumorigenesis, and anomalies. Abbreviations: CAV1, caveolin 1; GSK3\u03b2, glycogen synthase kinase 3\u03b2; INPP5E, inositol polyphosphate-5-phosphatase E; IGF1R, insulin-like growth factor 1 receptor; IR, insulin receptor; PI3K, phosphatidylinositol-3-kinase; PIP2, phosphatidylinositol 4,5-bisphosphate; PIP3, phosphatidylinositol 3,4,5-triphosphate.3.1. TCHPTCHP deletion has several effects on lipid metabolism associated with primary cilia in both cultured cells and mice (Figure 3A). While the primary cilia of preadipocytes are normally elongated initially and then gradually shorten during differentiation [141], TCHP KO results in longer than normal primary cilia during differentiation [79]. Various receptors located in and/or around primary cilia are involved in adipogenesis [142], including the insulin receptor (IR) [79], insulin-like growth factor 1 receptor (IGF1R) [143,144,145], Patched-1 and Smoothened [146], and free fatty acid receptor 4 [78]. During adipogenesis, IR/IGF1R\u2013AKT signaling is positively modulated by lipid rafts [147,148], which are membrane nanodomains that regulate multiple cellular functions, including proliferation, differentiation, and apoptosis [149,150,151,152,153,154,155,156]. Lipid rafts act as hubs for recruitment of many signaling proteins, including components of the PI3K\u2013AKT cascade, in response to internal and external stimuli [153,157,158,159,160,161,162]. Studies in the mouse mesenchymal progenitor cell line C3H10T1/2 have shown that exposure of the cells to adipogenic stimuli leads to accumulation of lipid rafts containing caveolin 1 (CAV1) or ganglioside GM3 around the base of primary cilia [79]. TCHP KD in these cells does not affect the localization of IRs but suppresses accumulation of CAV1- or GM3-positive lipid rafts around the ciliary base, which inhibits Akt signaling and disrupts cell differentiation to adipocytes [79]. Notably, TCHP KO mice are resistant to the deleterious metabolic consequences of a high-fat diet [79]. Taken together, these findings suggest that TCHP\u2013AKT signaling may be a novel therapeutic target for the development of anti-obesity agents.In addition to the accumulation of lipid rafts, TCHP KD in C3H10T1/2 cells reduces the abundance of actin filaments in primary cilia compared with control cells [163]; however, simultaneous KD of intraflagellar transport protein 88, which is required for ciliogenesis [164], ameliorates the effects of TCHP KD on cilia length, actin filamentation, CAV1- or GM3-positive lipid raft accumulation, AKT phosphorylation, and adipogenesis [79,163]. Actin filaments are thought to play important roles in the dynamics of CAV1 [165,166,167]. These findings suggest that TCHP may regulate AKT activity through effects on lipid raft dynamics around primary cilia [79,163].Modulation of lipid rafts has attracted attention as a promising approach to various diseases in addition to obesity, including cancer and inflammation [162,168,169,170]. In addition to AKT, signaling proteins associated with other cascades, including the mitogen-activated protein kinase pathway and the Janus kinase-signal transducer and activator of transcription pathway, are assembled in lipid rafts and positively and/or negatively regulate signal transduction into the cell [129,133,134,135,136,137,138]. Prostate cancer and melanoma are both associated with a reduction in the abundance of primary cilia [65,67,72,171,172], and hyperactivation of lipid raft\u2013AKT signaling is also observed in these cancers [21,154,156,170,173]. Stimulation of ciliogenesis via inhibition of lipid raft accumulation and suppression of lipid raft\u2013AKT signaling around primary cilia may thus be a potential method for inhibiting the growth of melanoma and prostate cancer [163]. Nevertheless, the relationship between primary cilia and lipid rafts remains to be fully elucidated [174].3.2. INPP5EThe activity of AKT is decreased by dephosphorylation of PI(3,4,5)P3 to PI(4,5)P2 by phosphatase and tensin homolog deleted from chromosome 10 (PTEN) and of PI(3,4,5)P3 to PI(3,4)P2 by several 5\u2032-phosphatases, including inositol polyphosphate-5-phosphatase (INPP5) D, INPP5E, INPP5J, and INPP5K [135,175]. Among these phosphatases, INPP5E is located in primary cilia and is a regulator of AKT signaling at this location [92].Mutations in INPP5E are associated with Joubert syndrome, a recessive neurodevelopmental ciliopathy that results in underdeveloped and malformed brain structures. The pathogenic mutations in INPP5E decrease the dephosphorylation of PI(3,4,5)P3, resulting in hyperactivation of AKT and suppression of ciliogenesis [176] (Figure 3B). In mice, conditional inactivation of INPP5E in kidney epithelial cells causes hyperactivation of AKT and mTORC1, reduced numbers of primary cilia, and polycystic kidneys [177]. Additionally, deletion of INPP5E in mouse neurons causes aberrant activation of AKT signaling and impairs axon tract development [140]. KD of inpp5e in zebrafish also increases PI(3,4,5)P3 accumulation and suppresses the formation of primary cilia [178].Mutations in INPP5E are also found in various cancers, including stomach adenocarcinoma, glioblastoma multiforme, and lung adenocarcinoma [179]. Such mutations frequently involve the phosphatase domain [179], suggesting that dysregulation of AKT signaling and primary cilia may contribute to tumor growth. In addition to the regulation of ciliogenesis, INPP5E also controls chromosomal integrity [179]. The mechanisms underlying oncogenesis associated with INPP5E mutations remain largely unknown.3.3. VHLVHL is an E3 ubiquitin ligase that plays an important role in the cellular response to hypoxia via its regulation of substrates such as the transcription factors hypoxia-inducible factor (HIF) 1\u03b1 and 2\u03b1 [180]. Under normoxic conditions, VHL binds to HIF1\u03b1 that has been hydroxylated at proline (Pro) 402 and/or 564 by the enzymes prolyl-4 hydroxylase domain (PHD) 1, 2, and 3 and subsequently ubiquitinates HIF1\u03b1, leading to its degradation [181]. Under hypoxic conditions, however, the activities of PHD1\u20133 are inhibited, which prevents VHL-mediated ubiquitination and degradation of HIF1\u03b1 [182] and increases the transcription of hypoxia-related genes.Mutation of VHL is associated with von Hippel\u2013Lindau syndrome, a rare inherited disorder that causes malignant and benign neoplasms and multiple cysts, especially in the kidney [183,184]. Impairment of VHL in human renal clear cell carcinoma (RCC) has been shown to inhibit the formation of primary cilia [58,137,185]. In mouse embryonic fibroblasts, VHL binds to AKT1 hydroxylated at Pro125 and Pro314 by Phd2, which results in suppression of AKT kinase activity but does not increase its degradation [186,187]. In human RPE cells, loss of primary cilia caused by VHL depletion can be rescued by AKT inhibition [188].Biallelic inactivation of VHL is the most frequent cause of RCC [189,190,191]. This disease is associated with a severe reduction in the frequency of primary cilia [59] and hyperactivation of the PI3K\u2013AKT signaling cascade [192]. Interestingly, inhibition of AKT in VHL-deficient cells decreases the expression of AURKA [188]. Therefore, inhibition of VHL\u2013AKT signaling may be one approach to suppress the proliferation of RCC through stimulation of ciliogenesis. 4. Future DirectionsThe information reviewed here illustrates how elucidation of the molecular mechanisms underlying signaling by AURKA and AKT associated with primary cilia may provide valuable insights into both the physiological and pathological functions of primary cilia. In turn, these insights lay the foundation for the development of novel therapeutics for cilia-related disorders. Some approaches to drug development may include (i) small molecules that modulate the interaction between kinases and the binding partners that regulate primary cilia, (ii) small molecules that selectively promote degradation of the kinases or their binding partners, and (iii) identifying novel and druggable AURKA and AKT binding partners crucial to their functions in the context of primary cilia.Intense work over the past few decades has resulted in the development of inhibitors that target ATP-binding sites and/or allosteric sites in multiple kinases, including AURKA and AKT [6,26,193]. More recent advances have enabled the development of agents that interfere with binding of kinases to scaffold proteins that support kinase activation [11,13,24,194,195,196]. During prophase and metaphase, AURKA is recruited to microtubules in mitotic spindles through the interaction between the C-terminal catalytic domain of AURKA and the N-terminus of TPX2 [197,198]. As noted earlier, this interaction is crucial for regulating the phosphorylation state and activity of AURKA, and, importantly, it is also druggable [194]. The small molecule AURKA inhibitor AurkinA acts by binding to the hydrophobic pocket of AURKA where TPX2 is normally accommodated through a conserved Tyr-Ser-Tyr motif in TPX2 [11]. Binding of AurkinA causes mislocalization of AURKA from the microtubules in mitotic spindles and inhibits its catalytic activity without affecting ATP binding [11]. Novel approaches are currently being developed to find chemical spaces in AURKA that can modulate its protein\u2013protein interactions [199,200,201].Technologies that lead to targeted protein degradation, such as proteolysis-targeting chimeras (PROTACs), protein-catalyzed capture agents (PCCs), and specific and nongenetic inhibitors of apoptosis protein-dependent protein erasers, have been successfully applied to develop novel kinase inhibitors [202,203,204,205,206]. For example, a PROTAC consisting of alisertib, a clinically used ATP-competitive inhibitor of AURKA [207], and thalidomide, which induces protein degradation via cereblon-containing ubiquitin ligase, results in proteolysis of AURKA and arrest of the cell cycle in MV4-11 human acute myeloid leukemia cells [5]. AKT can also be selectively degraded by a PROTAC that utilizes ipatasertib and lenalidomide as the ATP-competitive AKT inhibitor and degradation inducer, respectively [208]. Similarly, AKT degradation is induced by a PCC that employs a peptide derived from human immunodeficiency virus type 1 Tat protein as the cell-penetrating peptide and an HIF1\u03b1 peptide as a VHL ligand [209]. In addition to the kinases themselves, protein degradation systems have also been designed to target kinase modulators. The protein bromodomain containing 4 (BRD4) binds to P-TEFb, a heterodimer of cyclin-dependent kinase 9 (CDK9) and cyclin T1 and promotes transcriptional elongation through phosphorylation of RNA polymerase II [210,211]. A PROTAC composed of pomalidomide linked to OTX-015, a small molecule that binds to BRD4 at the bromodomain and extra-terminal domain, induces BRD4 degradation and consequently decreases the activity of CDK9 and expression of its downstream target, MYC [212]. Thus, targeted protein degradation can be applied to develop novel inhibitors of protein\u2013protein interactions [213].Subcellular compartment-specific signaling can be analyzed using F\u00f6rster or fluorescence resonance energy transfer (FRET) sensors fused to signal peptides. FRET sensors have been developed to analyze multiple signaling pathways, including those involving AURKA [214], AKT [139,215], cyclic adenosine monophosphate (AMP) [216,217], and calcium [218]. For example, an AURKA FRET sensor composed of AURKA within an eGFP and mCherry donor\u2013acceptor fluorophore pair was based on the conformational change exhibited by AURKA upon autophosphorylation of Thr288 [214]. Phosphopeptide-binding domains (PBDs) have also been employed in the development of FRET biosensors to visualize kinase activity [219]. For example, Eevee-iAkt, a FRET biosensor for AKT, is composed of YPet as the acceptor fluorophore, the Forkhead-associated domain of yeast Rad53 as the PBD, an optimized peptide derived from human GSK3\u03b2 as the AKT substrate sequence, and eCFP as the donor fluorophore [215]. Addition of the C-terminal region of human H-Ras and K-Ras to the C-terminal of Eevee-iAkt localizes the expression of Eevee-iAkt to raft and nonraft domains, respectively, and enables AKT activity in each domain to be analyzed [215]. Calcium and cyclic AMP signaling in primary cilia have also been successfully analyzed using FRET sensors. One example that has facilitated analysis of calcium signaling in primary cilia is composed of calmodulin as the calcium-binding domain, M13 as the calcium-bound calmodulin-binding domain, and eCFP and YPet as the donor and acceptor fluorophores, respectively. This sensor can be selectively expressed in primary cilia by linkage to the ciliary protein ADP ribosylation factor-like GTPase 13B (ARL13B) [218]. Similarly, fusion of ciliary proteins such as ARL13B with the adenylyl cyclase-coupled somatostatin receptor 3 has been employed to construct FRET sensors for analysis of cyclic AMP signaling in primary cilia [217,220]. Based on these studies, it seems likely that FRET sensors could also be constructed for the analysis of AURKA and AKT signaling localized in primary cilia. A complete picture of the interactomes of subcellular compartments, including primary cilia and lipid rafts, is gradually being deciphered by studies using other novel approaches, such as proximity mapping and stable isotope labeling using amino acids in cell culture [221,222,223]. These approaches have been successfully used to reveal the interactome of AURKA [27] and AKT [224].Thus, a combination of these techniques is likely to advance our understanding of the mechanisms regulating AURKA and AKT kinase signaling within and around primary cilia and may pave the way for the development of novel therapeutics for ciliopathies. AcknowledgmentsWe sincerely apologize to our colleagues whose important publications could not be cited in this review due to space limitations. We thank Anne M. O\u2019Rourke for editing a draft of this manuscript. Author ContributionsConceptualization, Y.N., D.Y. and M.I.; writing\u2014original draft preparation, Y.N.; writing\u2014review and editing, Y.N. and M.I.; visualization, T.S. and Y.N.; funding acquisition, Y.N., D.Y., T.S. and M.I. All authors have read and agreed to the published version of the manuscript. FundingThis work was supported in part by funding from the Japan Society for the Promotion of Science KAKENHI (19K07318 to Y.N., 20K07356 to D.Y., 18K06890 to T.S., and 21H02696 to M.I.), the Takeda Science Foundation (to Y.N., D.Y., and M.I.), and the Naito Foundation (to M.I.). Institutional Review Board StatementNot applicable. Informed Consent StatementNot applicable. Data Availability StatementNot applicable. Conflicts of InterestThe authors declare no conflict of interest. FootnotesPublisher\u2019s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. References1. Fabbro D., Cowan-Jacob S.W., Moebitz H. Ten things you should know about protein kinases: IUPHAR Review 14. Br. J. Pharm. 2015;172:2675\u20132700. doi:\u00a010.1111/bph.13096. [PMC free article] [PubMed] [CrossRef] [Google Scholar]2. Cohen P. The role of protein phosphorylation in human health and disease. The Sir Hans Krebs Medal Lecture. Eur. J. Biochem. 2001;268:5001\u20135010. doi:\u00a010.1046/j.0014-2956.2001.02473.x. [PubMed] [CrossRef] [Google Scholar]3. Iakoucheva L.M., Radivojac P., Brown C.J., O\u2019Connor T.R., Sikes J.G., Obradovic Z., Dunker A.K. The importance of intrinsic disorder for protein phosphorylation. Nucleic Acids Res. 2004;32:1037\u20131049. doi:\u00a010.1093/nar/gkh253. [PMC free article] [PubMed] [CrossRef] [Google Scholar]4. Kung J.E., Jura N. Structural Basis for the Non-catalytic Functions of Protein Kinases. Structure. 2016;24:7\u201324. doi:\u00a010.1016/j.str.2015.10.020. [PMC free article] [PubMed] [CrossRef] [Google Scholar]5. Adhikari B., Bozilovic J., Diebold M., Schwarz J.D., Hofstetter J., Schr\u00f6der M., Wanior M., Narain A., Vogt M., Dudvarski Stankovic N., et al.  PROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase. Nat. Chem. Biol. 2020;16:1179\u20131188. doi:\u00a010.1038/s41589-020-00652-y. [PMC free article] [PubMed] [CrossRef] [Google Scholar]6. Lazaro G., Kostaras E., Vivanco I. Inhibitors in AKTion: ATP-competitive vs allosteric. Biochem. Soc. Trans. 2020;48:933\u2013943. doi:\u00a010.1042/BST20190777. [PMC free article] [PubMed] [CrossRef] [Google Scholar]7. Willems E., Dedobbeleer M., Digregorio M., Lombard A., Lumapat P.N., Rogister B. The functional diversity of Aurora kinases: A comprehensive review. Cell Div. 2018;13:7. doi:\u00a010.1186/s13008-018-0040-6. [PMC free article] [PubMed] [CrossRef] [Google Scholar]8. Kostaras E., Kaserer T., Lazaro G., Heuss S.F., Hussain A., Casado P., Hayes A., Yandim C., Palaskas N., Yu Y., et al.  A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity. Br. J. Cancer. 2020;123:542\u2013555. doi:\u00a010.1038/s41416-020-0889-4. [PMC free article] [PubMed] [CrossRef] [Google Scholar]9. Ruff E.F., Muretta J.M., Thompson A.R., Lake E.W., Cyphers S., Albanese S.K., Hanson S.M., Behr J.M., Thomas D.D., Chodera J.D., et al.  A dynamic mechanism for allosteric activation of Aurora kinase A by activation loop phosphorylation. eLife. 2018;7:e32766. doi:\u00a010.7554/eLife.32766. [PMC free article] [PubMed] [CrossRef] [Google Scholar]10. Hammond D., Zeng K., Espert A., Bastos R.N., Baron R.D., Gruneberg U., Barr F.A. Melanoma-associated mutations in protein phosphatase 6 cause chromosome instability and DNA damage owing to dysregulated Aurora-A. J. Cell Sci. 2013;126:3429\u20133440. doi:\u00a010.1242/jcs.128397. [PubMed] [CrossRef] [Google Scholar]11. Jane\u010dek M., Rossmann M., Sharma P., Emery A., Huggins D.J., Stockwell S.R., Stokes J.E., Tan Y.S., Almeida E.G., Hardwick B., et al.  Allosteric modulation of AURKA kinase activity by a small-molecule inhibitor of its protein-protein interaction with TPX2. Sci. Rep. 2016;6:28528. doi:\u00a010.1038/srep28528. [PMC free article] [PubMed] [CrossRef] [Google Scholar]12. Bayliss R., Burgess S.G., McIntyre P.J. Switching Aurora-A kinase on and off at an allosteric site. FEBS J. 2017;284:2947\u20132954. doi:\u00a010.1111/febs.14069. [PubMed] [CrossRef] [Google Scholar]13. Levinson N.M. The multifaceted allosteric regulation of Aurora kinase A. Biochem. J. 2018;475:2025\u20132042. doi:\u00a010.1042/BCJ20170771. [PMC free article] [PubMed] [CrossRef] [Google Scholar]14. Lake E.W., Muretta J.M., Thompson A.R., Rasmussen D.M., Majumdar A., Faber E.B., Ruff E.F., Thomas D.D., Levinson N.M. Quantitative conformational profiling of kinase inhibitors reveals origins of selectivity for Aurora kinase activation states. Proc. Natl. Acad. Sci. USA. 2018;115:E11894\u2013E11903. doi:\u00a010.1073/pnas.1811158115. [PMC free article] [PubMed] [CrossRef] [Google Scholar]15. Otto T., Horn S., Brockmann M., Eilers U., Sch\u00fcttrumpf L., Popov N., Kenney A.M., Schulte J.H., Beijersbergen R., Christiansen H., et al.  Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell. 2009;15:67\u201378. doi:\u00a010.1016/j.ccr.2008.12.005. [PubMed] [CrossRef] [Google Scholar]16. Brodeur G.M., Seeger R.C., Schwab M., Varmus H.E., Bishop J.M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984;224:1121\u20131124. doi:\u00a010.1126/science.6719137. [PubMed] [CrossRef] [Google Scholar]17. Lee J.K., Phillips J.W., Smith B.A., Park J.W., Stoyanova T., McCaffrey E.F., Baertsch R., Sokolov A., Meyerowitz J.G., Mathis C., et al.  N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. Cancer Cell. 2016;29:536\u2013547. doi:\u00a010.1016/j.ccell.2016.03.001. [PMC free article] [PubMed] [CrossRef] [Google Scholar]18. Brockmann M., Poon E., Berry T., Carstensen A., Deubzer H.E., Rycak L., Jamin Y., Thway K., Robinson S.P., Roels F., et al.  Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma. Cancer Cell. 2013;24:75\u201389. doi:\u00a010.1016/j.ccr.2013.05.005. [PMC free article] [PubMed] [CrossRef] [Google Scholar]19. Gustafson W.C., Meyerowitz J.G., Nekritz E.A., Chen J., Benes C., Charron E., Simonds E.F., Seeger R., Matthay K.K., Hertz N.T., et al.  Drugging MYCN through an allosteric transition in Aurora kinase A. Cancer Cell. 2014;26:414\u2013427. doi:\u00a010.1016/j.ccr.2014.07.015. [PMC free article] [PubMed] [CrossRef] [Google Scholar]20. Lu\u010di\u0107 I., Rathinaswamy M.K., Truebestein L., Hamelin D.J., Burke J.E., Leonard T.A. Conformational sampling of membranes by Akt controls its activation and inactivation. Proc. Natl. Acad. Sci. USA. 2018;115:E3940\u2013E3949. doi:\u00a010.1073/pnas.1716109115. [PMC free article] [PubMed] [CrossRef] [Google Scholar]21. Sugiyama M.G., Fairn G.D., Antonescu C.N. Akt-ing Up Just About Everywhere: Compartment-Specific Akt Activation and Function in Receptor Tyrosine Kinase Signaling. Front. Cell Dev. Biol. 2019;7:70. doi:\u00a010.3389/fcell.2019.00070. [PMC free article] [PubMed] [CrossRef] [Google Scholar]22. Korobeynikov V., Deneka A.Y., Golemis E.A. Mechanisms for nonmitotic activation of Aurora-A at cilia. Biochem. Soc. Trans. 2017;45:37\u201349. doi:\u00a010.1042/BST20160142. [PMC free article] [PubMed] [CrossRef] [Google Scholar]23. Bertolin G., Tramier M. Insights into the non-mitotic functions of Aurora kinase A: More than just cell division. Cell. Mol. Life Sci. CMLS. 2020;77:1031\u20131047. doi:\u00a010.1007/s00018-019-03310-2. [PubMed] [CrossRef] [Google Scholar]24. Berndt N., Karim R.M., Sch\u00f6nbrunn E. Advances of small molecule targeting of kinases. Curr. Opin. Chem. Biol. 2017;39:126\u2013132. doi:\u00a010.1016/j.cbpa.2017.06.015. [PMC free article] [PubMed] [CrossRef] [Google Scholar]25. De Almeida Magalh\u00e3es T., de Sousa G.R., Alencastro Veiga Cruzeiro G., Tone L.G., Valera E.T., Borges K.S. The therapeutic potential of Aurora kinases targeting in glioblastoma: From preclinical research to translational oncology. J. Mol. Med. 2020;98:495\u2013512. doi:\u00a010.1007/s00109-020-01895-x. [PubMed] [CrossRef] [Google Scholar]26. Martorana F., Motta G., Pavone G., Motta L., Stella S., Vitale S.R., Manzella L., Vigneri P. AKT Inhibitors: New Weapons in the Fight Against Breast Cancer? Front. Pharmacol. 2021;12:662232. doi:\u00a010.3389/fphar.2021.662232. [PMC free article] [PubMed] [CrossRef] [Google Scholar]27. Arslanhan M.D., Rauniyar N., Yates J.R., III, Firat-Karalar E.N. Aurora Kinase A proximity map reveals centriolar satellites as regulators of its ciliary function. EMBO Rep. 2021;22:e51902. doi:\u00a010.15252/embr.202051902. [PMC free article] [PubMed] [CrossRef] [Google Scholar]28. Anvarian Z., Mykytyn K., Mukhopadhyay S., Pedersen L.B., Christensen S.T. Cellular signalling by primary cilia in development, organ function and disease. Nat. Rev. Nephrol. 2019;15:199\u2013219. doi:\u00a010.1038/s41581-019-0116-9. [PMC free article] [PubMed] [CrossRef] [Google Scholar]29. Malicki J.J., Johnson C.A. The Cilium: Cellular Antenna and Central Processing Unit. Trends Cell Biol. 2017;27:126\u2013140. doi:\u00a010.1016/j.tcb.2016.08.002. [PMC free article] [PubMed] [CrossRef] [Google Scholar]30. Goto H., Inoko A., Inagaki M. Cell cycle progression by the repression of primary cilia formation in proliferating cells. Cell. Mol. Life Sci. 2013;70:3893\u20133905. doi:\u00a010.1007/s00018-013-1302-8. [PMC free article] [PubMed] [CrossRef] [Google Scholar]31. Izawa I., Goto H., Kasahara K., Inagaki M. Current topics of functional links between primary cilia and cell cycle. Cilia. 2015;4:12. doi:\u00a010.1186/s13630-015-0021-1. [PMC free article] [PubMed] [CrossRef] [Google Scholar]32. Goto H., Inaba H., Inagaki M. Mechanisms of ciliogenesis suppression in dividing cells. Cell. Mol. Life Sci. 2017;74:881\u2013890. doi:\u00a010.1007/s00018-016-2369-9. [PMC free article] [PubMed] [CrossRef] [Google Scholar]33. Nishimura Y., Kasahara K., Shiromizu T., Watanabe M., Inagaki M. Primary cilia as signaling hubs in health and disease. Adv. Sci. 2019;6:1801138. doi:\u00a010.1002/advs.201801138. [PMC free article] [PubMed] [CrossRef] [Google Scholar]34. Kasahara K., Inagaki M. Primary ciliary signaling: Links with the cell cycle. Trends Cell Biol. 2021;31:954\u2013964. doi:\u00a010.1016/j.tcb.2021.07.009. [PubMed] [CrossRef] [Google Scholar]35. Garcia G., Raleigh D.R., Reiter J.F. How the Ciliary Membrane Is Organized Inside-Out to Communicate Outside-In. Curr. Biol. 2018;28:R421\u2013R434. doi:\u00a010.1016/j.cub.2018.03.010. [PMC free article] [PubMed] [CrossRef] [Google Scholar]36. Elliott K.H., Brugmann S.A. Sending mixed signals: Cilia-dependent signaling during development and disease. Dev. Biol. 2018;447:28\u201341. doi:\u00a010.1016/j.ydbio.2018.03.007. [PMC free article] [PubMed] [CrossRef] [Google Scholar]37. Wang L., Dynlacht B.D. The regulation of cilium assembly and disassembly in development and disease. Development. 2018;145 doi:\u00a010.1242/dev.151407. [PMC free article] [PubMed] [CrossRef] [Google Scholar]38. Nishimura Y., Kasahara K., Inagaki M. Intermediate filaments and IF-associated proteins: From cell architecture to cell proliferation. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 2019;95:479\u2013493. doi:\u00a010.2183/pjab.95.034. [PMC free article] [PubMed] [CrossRef] [Google Scholar]39. Bernab\u00e9-Rubio M., Alonso M.A. Routes and machinery of primary cilium biogenesis. Cell. Mol. Life Sci. 2017;74:4077\u20134095. doi:\u00a010.1007/s00018-017-2570-5. [PubMed] [CrossRef] [Google Scholar]40. Mirvis M., Stearns T., James Nelson W. Cilium structure, assembly, and disassembly regulated by the cytoskeleton. Biochem. J. 2018;475:2329\u20132353. doi:\u00a010.1042/BCJ20170453. [PMC free article] [PubMed] [CrossRef] [Google Scholar]41. Hossain D., Tsang W.Y. The role of ubiquitination in the regulation of primary cilia assembly and disassembly. Semin. Cell Dev. Biol. 2019;93:145\u2013152. doi:\u00a010.1016/j.semcdb.2018.09.005. [PubMed] [CrossRef] [Google Scholar]42. Wang B., Liang Z., Liu P. Functional aspects of primary cilium in signaling, assembly and microenvironment in cancer. J. Cell. Physiol. 2021;236:3207\u20133219. doi:\u00a010.1002/jcp.30117. [PMC free article] [PubMed] [CrossRef] [Google Scholar]43. Tucker R.W., Pardee A.B., Fujiwara K. Centriole ciliation is related to quiescence and DNA synthesis in 3T3 cells. Cell. 1979;17:527\u2013535. doi:\u00a010.1016/0092-8674(79)90261-7. [PubMed] [CrossRef] [Google Scholar]44. Tucker R.W., Scher C.D., Stiles C.D. Centriole deciliation associated with the early response of 3T3 cells to growth factors but not to SV40. Cell. 1979;18:1065\u20131072. doi:\u00a010.1016/0092-8674(79)90219-8. [PubMed] [CrossRef] [Google Scholar]45. Rieder C.L., Jensen C.G., Jensen L.C.W. The resorption of primary cilia during mitosis in a vertebrate (PtK1) cell line. J. Ultrastruct. Res. 1979;68:173\u2013185. doi:\u00a010.1016/S0022-5320(79)90152-7. [PubMed] [CrossRef] [Google Scholar]46. Pugacheva E.N., Jablonski S.A., Hartman T.R., Henske E.P., Golemis E.A. HEF1-dependent Aurora A activation induces disassembly of the primary cilium. Cell. 2007;129:1351\u20131363. doi:\u00a010.1016/j.cell.2007.04.035. [PMC free article] [PubMed] [CrossRef] [Google Scholar]47. Inoko A., Matsuyama M., Goto H., Ohmuro-Matsuyama Y., Hayashi Y., Enomoto M., Ibi M., Urano T., Yonemura S., Kiyono T., et al.  Trichoplein and Aurora A block aberrant primary cilia assembly in proliferating cells. J. Cell Biol. 2012;197:391\u2013405. doi:\u00a010.1083/jcb.201106101. [PMC free article] [PubMed] [CrossRef] [Google Scholar]48. Kasahara K., Kawakami Y., Kiyono T., Yonemura S., Kawamura Y., Era S., Matsuzaki F., Goshima N., Inagaki M. Ubiquitin-proteasome system controls ciliogenesis at the initial step of axoneme extension. Nat. Commun. 2014;5:5081. doi:\u00a010.1038/ncomms6081. [PMC free article] [PubMed] [CrossRef] [Google Scholar]49. Inaba H., Goto H., Kasahara K., Kumamoto K., Yonemura S., Inoko A., Yamano S., Wanibuchi H., He D., Goshima N., et al.  Ndel1 suppresses ciliogenesis in proliferating cells by regulating the trichoplein-Aurora A pathway. J. Cell Biol. 2016;212:409\u2013423. doi:\u00a010.1083/jcb.201507046. [PMC free article] [PubMed] [CrossRef] [Google Scholar]50. Kasahara K., Aoki H., Kiyono T., Wang S., Kagiwada H., Yuge M., Tanaka T., Nishimura Y., Mizoguchi A., Goshima N., et al.  EGF receptor kinase suppresses ciliogenesis through activation of USP8 deubiquitinase. Nat. Commun. 2018;9:758. doi:\u00a010.1038/s41467-018-03117-y. [PMC free article] [PubMed] [CrossRef] [Google Scholar]51. Urdiciain A., Erausquin E., Mel\u00e9ndez B., Rey J.A., Idoate M.A., Castresana J.S. Tubastatin A, an inhibitor of HDAC6, enhances temozolomide\u2014induced apoptosis and reverses the malignant phenotype of glioblastoma cells. Int. J. Oncol. 2019;54:1797\u20131808. doi:\u00a010.3892/ijo.2019.4739. [PubMed] [CrossRef] [Google Scholar]52. Chen Q., Li J., Yang X., Ma J., Gong F., Liu Y. Prdx1 promotes the loss of primary cilia in esophageal squamous cell carcinoma. BMC Cancer. 2020;20:372.  doi:\u00a010.1186/s12885-020-06898-y. [PMC free article] [PubMed] [CrossRef] [Google Scholar]53. Rocha C., Papon L., Cacheux W., Marques Sousa P., Lascano V., Tort O., Giordano T., Vacher S., Lemmers B., Mariani P., et al.  Tubulin glycylases are required for primary cilia, control of cell proliferation and tumor development in colon. EMBO J. 2014;33:2247\u20132260. doi:\u00a010.15252/embj.201488466. [PMC free article] [PubMed] [CrossRef] [Google Scholar]54. Gradilone S.A., Radtke B.N., Bogert P.S., Huang B.Q., Gajdos G.B., LaRusso N.F. HDAC6 inhibition restores ciliary expression and decreases tumor growth. Cancer Res. 2013;73:2259\u20132270. doi:\u00a010.1158/0008-5472.CAN-12-2938. [PMC free article] [PubMed] [CrossRef] [Google Scholar]55. Mansini A.P., Peixoto E., Thelen K.M., Gaspari C., Jin S., Gradilone S.A. The cholangiocyte primary cilium in health and disease. Biochim. Biophys. Acta. 2018;1864:1245\u20131253. doi:\u00a010.1016/j.bbadis.2017.06.006. [PMC free article] [PubMed] [CrossRef] [Google Scholar]56. Seeley E.S., Carriere C., Goetze T., Longnecker D.S., Korc M. Pancreatic cancer and precursor pancreatic intraepithelial neoplasia lesions are devoid of primary cilia. Cancer Res. 2009;69:422\u2013430. doi:\u00a010.1158/0008-5472.CAN-08-1290. [PMC free article] [PubMed] [CrossRef] [Google Scholar]57. Kobayashi T., Nakazono K., Tokuda M., Mashima Y., Dynlacht B.D., Itoh H. HDAC2 promotes loss of primary cilia in pancreatic ductal adenocarcinoma. EMBO Rep. 2017;18:334\u2013343. doi:\u00a010.15252/embr.201541922. [PMC free article] [PubMed] [CrossRef] [Google Scholar]58. Esteban M.A., Harten S.K., Tran M.G., Maxwell P.H. Formation of primary cilia in the renal epithelium is regulated by the von Hippel-Lindau tumor suppressor protein. J. Am. Soc. Nephrol. 2006;17:1801\u20131806. doi:\u00a010.1681/ASN.2006020181. [PubMed] [CrossRef] [Google Scholar]59. Schraml P., Frew I.J., Thoma C.R., Boysen G., Struckmann K., Krek W., Moch H. Sporadic clear cell renal cell carcinoma but not the papillary type is characterized by severely reduced frequency of primary cilia. Mod. Pathol. 2009;22:31\u201336. doi:\u00a010.1038/modpathol.2008.132. [PubMed] [CrossRef] [Google Scholar]60. Basten S.G., Willekers S., Vermaat J.S., Slaats G.G., Voest E.E., van Diest P.J., Giles R.H. Reduced cilia frequencies in human renal cell carcinomas versus neighboring parenchymal tissue. Cilia. 2013;2:2. doi:\u00a010.1186/2046-2530-2-2. [PMC free article] [PubMed] [CrossRef] [Google Scholar]61. Dere R., Perkins A.L., Bawa-Khalfe T., Jonasch D., Walker C.L. beta-catenin links von Hippel-Lindau to aurora kinase A and loss of primary cilia in renal cell carcinoma. J. Am. Soc. Nephrol. 2015;26:553\u2013564. doi:\u00a010.1681/ASN.2013090984. [PMC free article] [PubMed] [CrossRef] [Google Scholar]62. Bhattacharya R., Kwon J., Ali B., Wang E., Patra S., Shridhar V., Mukherjee P. Role of hedgehog signaling in ovarian cancer. Clin. Cancer Res. 2008;14:7659\u20137666. doi:\u00a010.1158/1078-0432.CCR-08-1414. [PubMed] [CrossRef] [Google Scholar]63. Egeberg D.L., Lethan M., Manguso R., Schneider L., Awan A., Jorgensen T.S., Byskov A.G., Pedersen L.B., Christensen S.T. Primary cilia and aberrant cell signaling in epithelial ovarian cancer. Cilia. 2012;1:15. doi:\u00a010.1186/2046-2530-1-15. [PMC free article] [PubMed] [CrossRef] [Google Scholar]64. Yuan K., Frolova N., Xie Y., Wang D., Cook L., Kwon Y.J., Steg A.D., Serra R., Frost A.R. Primary cilia are decreased in breast cancer: Analysis of a collection of human breast cancer cell lines and tissues. J. Histochem. Cytochem. 2010;58:857\u2013870. doi:\u00a010.1369/jhc.2010.955856. [PMC free article] [PubMed] [CrossRef] [Google Scholar]65. Hassounah N.B., Nagle R., Saboda K., Roe D.J., Dalkin B.L., McDermott K.M. Primary cilia are lost in preinvasive and invasive prostate cancer. PLoS ONE. 2013;8:e68521.  doi:\u00a010.1371/journal.pone.0068521. [PMC free article] [PubMed] [CrossRef] [Google Scholar]66. Qie Y., Wang L., Du E., Chen S., Lu C., Ding N., Yang K., Xu Y. TACC3 promotes prostate cancer cell proliferation and restrains primary cilium formation. Exp. Cell Res. 2020;390:111952. doi:\u00a010.1016/j.yexcr.2020.111952. [PubMed] [CrossRef] [Google Scholar]67. Kim J., Dabiri S., Seeley E.S. Primary cilium depletion typifies cutaneous melanoma in situ and malignant melanoma. PLoS ONE. 2011;6:e27410.  doi:\u00a010.1371/journal.pone.0027410. [PMC free article] [PubMed] [CrossRef] [Google Scholar]68. Zingg D., Debbache J., Pe\u00f1a-Hern\u00e1ndez R., Antunes A.T., Schaefer S.M., Cheng P.F., Zimmerli D., Haeusel J., Cal\u00e7ada R.R., Tuncer E., et al.  EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation. Cancer Cell. 2018;34:69\u201384. doi:\u00a010.1016/j.ccell.2018.06.001. [PubMed] [CrossRef] [Google Scholar]69. Ho L., Ali S.A., Al-Jazrawe M., Kandel R., Wunder J.S., Alman B.A. Primary cilia attenuate hedgehog signalling in neoplastic chondrocytes. Oncogene. 2013;32:5388\u20135396. doi:\u00a010.1038/onc.2012.588. [PMC free article] [PubMed] [CrossRef] [Google Scholar]70. Xiang W., Guo F., Cheng W., Zhang J., Huang J., Wang R., Ma Z., Xu K. HDAC6 inhibition suppresses chondrosarcoma by restoring the expression of primary cilia. Oncol. Rep. 2017;38:229\u2013236. doi:\u00a010.3892/or.2017.5694. [PubMed] [CrossRef] [Google Scholar]71. Liu H., Kiseleva A.A., Golemis E.A. Ciliary signalling in cancer. Nat. Rev. Cancer. 2018;18:511\u2013524. doi:\u00a010.1038/s41568-018-0023-6. [PMC free article] [PubMed] [CrossRef] [Google Scholar]72. Fabbri L., Bost F., Mazure N.M. Primary Cilium in Cancer Hallmarks. Int. J. Mol. Sci. 2019;20:1336.  doi:\u00a010.3390/ijms20061336. [PMC free article] [PubMed] [CrossRef] [Google Scholar]73. Higgins M., Obaidi I., McMorrow T. Primary cilia and their role in cancer. Oncol. Lett. 2019;17:3041\u20133047. doi:\u00a010.3892/ol.2019.9942. [PMC free article] [PubMed] [CrossRef] [Google Scholar]74. Shiromizu T., Yuge M., Kasahara K., Yamakawa D., Matsui T., Bessho Y., Inagaki M., Nishimura Y. Targeting E3 Ubiquitin Ligases and Deubiquitinases in Ciliopathy and Cancer. Int. J. Mol. Sci. 2020;21:5962.  doi:\u00a010.3390/ijms21175962. [PMC free article] [PubMed] [CrossRef] [Google Scholar]75. Peixoto E., Richard S., Pant K., Biswas A., Gradilone S.A. The primary cilium: Its role as a tumor suppressor organelle. Biochem. Pharm. 2020;175:113906. doi:\u00a010.1016/j.bcp.2020.113906. [PMC free article] [PubMed] [CrossRef] [Google Scholar]76. Halder P., Khatun S., Majumder S. Freeing the brake: Proliferation needs primary cilium to disassemble. J. Biosci. 2020;45 doi:\u00a010.1007/s12038-020-00090-x. [PubMed] [CrossRef] [Google Scholar]77. Mariman E.C., Vink R.G., Roumans N.J., Bouwman F.G., Stumpel C.T., Aller E.E., van Baak M.A., Wang P. The cilium: A cellular antenna with an influence on obesity risk. Br. J. Nutr. 2016;116:576\u2013592. doi:\u00a010.1017/S0007114516002282. [PubMed] [CrossRef] [Google Scholar]78. Hilgendorf K.I., Johnson C.T., Mezger A., Rice S.L., Norris A.M., Demeter J., Greenleaf W.J., Reiter J.F., Kopinke D., Jackson P.K. Omega-3 Fatty Acids Activate Ciliary FFAR4 to Control Adipogenesis. Cell. 2019;179:1289\u20131305.e1221. doi:\u00a010.1016/j.cell.2019.11.005. [PMC free article] [PubMed] [CrossRef] [Google Scholar]79. Yamakawa D., Katoh D., Kasahara K., Shiromizu T., Matsuyama M., Matsuda C., Maeno Y., Watanabe M., Nishimura Y., Inagaki M. Primary cilia-dependent lipid raft/caveolin dynamics regulate adipogenesis. Cell Rep. 2021;34:108817. doi:\u00a010.1016/j.celrep.2021.108817. [PubMed] [CrossRef] [Google Scholar]80. Han Y.M., Kang G.M., Byun K., Ko H.W., Kim J., Shin M.S., Kim H.K., Gil S.Y., Yu J.H., Lee B., et al.  Leptin-promoted cilia assembly is critical for normal energy balance. J. Clin. Investig. 2014;124:2193\u20132197. doi:\u00a010.1172/JCI69395. [PMC free article] [PubMed] [CrossRef] [Google Scholar]81. Ernst M.B., Wunderlich C.M., Hess S., Paehler M., Mesaros A., Koralov S.B., Kleinridders A., Husch A., Munzberg H., Hampel B., et al.  Enhanced Stat3 activation in POMC neurons provokes negative feedback inhibition of leptin and insulin signaling in obesity. J. Neurosci. 2009;29:11582\u201311593. doi:\u00a010.1523/JNEUROSCI.5712-08.2009. [PMC free article] [PubMed] [CrossRef] [Google Scholar]82. Mesaros A., Koralov S.B., Rother E., Wunderlich F.T., Ernst M.B., Barsh G.S., Rajewsky K., Bruning J.C. Activation of Stat3 signaling in AgRP neurons promotes locomotor activity. Cell Metab. 2008;7:236\u2013248. doi:\u00a010.1016/j.cmet.2008.01.007. [PubMed] [CrossRef] [Google Scholar]83. Davenport J.R., Watts A.J., Roper V.C., Croyle M.J., van Groen T., Wyss J.M., Nagy T.R., Kesterson R.A., Yoder B.K. Disruption of intraflagellar transport in adult mice leads to obesity and slow-onset cystic kidney disease. Curr. Biol. 2007;17:1586\u20131594. doi:\u00a010.1016/j.cub.2007.08.034. [PMC free article] [PubMed] [CrossRef] [Google Scholar]84. Oh E.C., Vasanth S., Katsanis N. Metabolic regulation and energy homeostasis through the primary Cilium. Cell Metab. 2015;21:21\u201331. doi:\u00a010.1016/j.cmet.2014.11.019. [PMC free article] [PubMed] [CrossRef] [Google Scholar]85. Siljee J.E., Wang Y., Bernard A.A., Ersoy B.A., Zhang S., Marley A., Von Zastrow M., Reiter J.F., Vaisse C. Subcellular localization of MC4R with ADCY3 at neuronal primary cilia underlies a common pathway for genetic predisposition to obesity. Nat. Genet. 2018;50:180\u2013185. doi:\u00a010.1038/s41588-017-0020-9. [PMC free article] [PubMed] [CrossRef] [Google Scholar]86. Grarup N., Moltke I., Andersen M.K., Dalby M., Vitting-Seerup K., Kern T., Mahendran Y., Jorsboe E., Larsen C.V.L., Dahl-Petersen I.K., et al.  Loss-of-function variants in ADCY3 increase risk of obesity and type 2 diabetes. Nat. Genet. 2018;50:172\u2013174. doi:\u00a010.1038/s41588-017-0022-7. [PMC free article] [PubMed] [CrossRef] [Google Scholar]87. Saeed S., Bonnefond A., Tamanini F., Mirza M.U., Manzoor J., Janjua Q.M., Din S.M., Gaitan J., Milochau A., Durand E., et al.  Loss-of-function mutations in ADCY3 cause monogenic severe obesity. Nat. Genet. 2018;50:175\u2013179. doi:\u00a010.1038/s41588-017-0023-6. [PubMed] [CrossRef] [Google Scholar]88. Loos R.J., Lindgren C.M., Li S., Wheeler E., Zhao J.H., Prokopenko I., Inouye M., Freathy R.M., Attwood A.P., Beckmann J.S., et al.  Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat. Genet. 2008;40:768\u2013775. doi:\u00a010.1038/ng.140. [PMC free article] [PubMed] [CrossRef] [Google Scholar]89. Sebo Z.L., Rodeheffer M.S. Assembling the adipose organ: Adipocyte lineage segregation and adipogenesis in vivo. Development. 2019;146 doi:\u00a010.1242/dev.172098. [PMC free article] [PubMed] [CrossRef] [Google Scholar]90. Marion V., Stoetzel C., Schlicht D., Messaddeq N., Koch M., Flori E., Danse J.M., Mandel J.L., Dollfus H. Transient ciliogenesis involving Bardet-Biedl syndrome proteins is a fundamental characteristic of adipogenic differentiation. Proc. Natl. Acad. Sci. USA. 2009;106:1820\u20131825. doi:\u00a010.1073/pnas.0812518106. [PMC free article] [PubMed] [CrossRef] [Google Scholar]91. Marion V., Mockel A., De Melo C., Obringer C., Claussmann A., Simon A., Messaddeq N., Durand M., Dupuis L., Loeffler J.P., et al.  BBS-induced ciliary defect enhances adipogenesis, causing paradoxical higher-insulin sensitivity, glucose usage, and decreased inflammatory response. Cell Metab. 2012;16:363\u2013377. doi:\u00a010.1016/j.cmet.2012.08.005. [PubMed] [CrossRef] [Google Scholar]92. Conduit S.E., Vanhaesebroeck B. Phosphoinositide lipids in primary cilia biology. Biochem. J. 2020;477:3541\u20133565. doi:\u00a010.1042/BCJ20200277. [PMC free article] [PubMed] [CrossRef] [Google Scholar]93. Jenks A.D., Vyse S., Wong J.P., Kostaras E., Keller D., Burgoyne T., Shoemark A., Tsalikis A., de la Roche M., Michaelis M., et al.  Primary Cilia Mediate Diverse Kinase Inhibitor Resistance Mechanisms in Cancer. Cell Rep. 2018;23:3042\u20133055. doi:\u00a010.1016/j.celrep.2018.05.016. [PMC free article] [PubMed] [CrossRef] [Google Scholar]94. Ritter A., Kreis N.N., Roth S., Friemel A., Jennewein L., Eichbaum C., Solbach C., Louwen F., Yuan J. Restoration of primary cilia in obese adipose-derived mesenchymal stem cells by inhibiting Aurora A or extracellular signal-regulated kinase. Stem Cell Res. Ther. 2019;10:255. doi:\u00a010.1186/s13287-019-1373-z. [PMC free article] [PubMed] [CrossRef] [Google Scholar]95. Carmena M., Earnshaw W.C., Glover D.M. The Dawn of Aurora Kinase Research: From Fly Genetics to the Clinic. Front. Cell Dev. Biol. 2015;3 doi:\u00a010.3389/fcell.2015.00073. [PMC free article] [PubMed] [CrossRef] [Google Scholar]96. Otto T., Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat. Rev. Cancer. 2017;17:93\u2013115. doi:\u00a010.1038/nrc.2016.138. [PMC free article] [PubMed] [CrossRef] [Google Scholar]97. Nikonova A.S., Astsaturov I., Serebriiskii I.G., Dunbrack R.L.J., Golemis E.A. Aurora A kinase (AURKA) in normal and pathological cell division. Cell. Mol. Life Sci. CMLS. 2013;70:661\u2013687. doi:\u00a010.1007/s00018-012-1073-7. [PMC free article] [PubMed] [CrossRef] [Google Scholar]98. Mardin B.R., Schiebel E. Breaking the ties that bind: New advances in centrosome biology. J. Cell Biol. 2012;197:11\u201318. doi:\u00a010.1083/jcb.201108006. [PMC free article] [PubMed] [CrossRef] [Google Scholar]99. Mardin B.R., Agircan F.G., Lange C., Schiebel E. Plk1 controls the Nek2A-PP1\u03b3 antagonism in centrosome disjunction. Curr. Biol. 2011;21:1145\u20131151. doi:\u00a010.1016/j.cub.2011.05.047. [PubMed] [CrossRef] [Google Scholar]100. Hutterer A., Berdnik D., Wirtz-Peitz F., Zigman M., Schleiffer A., Knoblich J.A. Mitotic activation of the kinase Aurora-A requires its binding partner Bora. Dev. Cell. 2006;11:147\u2013157. doi:\u00a010.1016/j.devcel.2006.06.002. [PubMed] [CrossRef] [Google Scholar]101. Hirota T., Kunitoku N., Sasayama T., Marumoto T., Zhang D., Nitta M., Hatakeyama K., Saya H. Aurora-A and an Interacting Activator, the LIM Protein Ajuba, Are Required for Mitotic Commitment in Human Cells. Cell. 2003;114:585\u2013598. doi:\u00a010.1016/S0092-8674(03)00642-1. [PubMed] [CrossRef] [Google Scholar]102. Giubettini M., Asteriti I.A., Scrofani J., De Luca M., Lindon C., Lavia P., Guarguaglini G. Control of Aurora-A stability through interaction with TPX2. J. Cell Sci. 2011;124:113\u2013122. doi:\u00a010.1242/jcs.075457. [PMC free article] [PubMed] [CrossRef] [Google Scholar]103. Tsai M.-Y., Zheng Y. Aurora A Kinase-Coated Beads Function as Microtubule-Organizing Centers and Enhance RanGTP-Induced Spindle Assembly. Curr. Biol. 2005;15:2156\u20132163. doi:\u00a010.1016/j.cub.2005.10.054. [PubMed] [CrossRef] [Google Scholar]104. Sasai K., Parant J.M., Brandt M.E., Carter J., Adams H.P., Stass S.A., Killary A.M., Katayama H., Sen S. Targeted disruption of Aurora A causes abnormal mitotic spindle assembly, chromosome misalignment and embryonic lethality. Oncogene. 2008;27:4122\u20134127. doi:\u00a010.1038/onc.2008.47. [PubMed] [CrossRef] [Google Scholar]105. Plotnikova O.V., Nikonova A.S., Loskutov Y.V., Kozyulina P.Y., Pugacheva E.N., Golemis E.A. Calmodulin activation of Aurora-A kinase (AURKA) is required during ciliary disassembly and in mitosis. Mol. Biol. Cell. 2012;23:2658\u20132670. doi:\u00a010.1091/mbc.e11-12-1056. [PMC free article] [PubMed] [CrossRef] [Google Scholar]106. Lee K.H., Johmura Y., Yu L.R., Park J.E., Gao Y., Bang J.K., Zhou M., Veenstra T.D., Yeon Kim B., Lee K.S. Identification of a novel Wnt5a-CK1varepsilon-Dvl2-Plk1-mediated primary cilia disassembly pathway. EMBO J. 2012;31:3104\u20133117. doi:\u00a010.1038/emboj.2012.144. [PMC free article] [PubMed] [CrossRef] [Google Scholar]107. Li D., Zhu J., Firozi P.F., Abbruzzese J.L., Evans D.B., Cleary K., Friess H., Sen S. Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin. Cancer Res. 2003;9:991\u2013997. [PubMed] [Google Scholar]108. Duncan C.G., Killela P.J., Payne C.A., Lampson B., Chen W.C., Liu J., Solomon D., Waldman T., Towers A.J., Gregory S.G., et al.  Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes. Oncotarget. 2010;1:265\u2013277. doi:\u00a010.18632/oncotarget.137. [PMC free article] [PubMed] [CrossRef] [Google Scholar]109. \u00c1lvarez-Satta M., Matheu A. Primary cilium and glioblastoma. Adv. Med. Oncol. 2018;10 doi:\u00a010.1177/1758835918801169. [PMC free article] [PubMed] [CrossRef] [Google Scholar]110. Nishizawa M., Izawa I., Inoko A., Hayashi Y., Nagata K., Yokoyama T., Usukura J., Inagaki M. Identification of trichoplein, a novel keratin filament-binding protein. J. Cell Sci. 2005;118:1081\u20131090. doi:\u00a010.1242/jcs.01667. [PubMed] [CrossRef] [Google Scholar]111. Ibi M., Zou P., Inoko A., Shiromizu T., Matsuyama M., Hayashi Y., Enomoto M., Mori D., Hirotsune S., Kiyono T., et al.  Trichoplein controls microtubule anchoring at the centrosome by binding to Odf2 and ninein. J. Cell Sci. 2011;124:857\u2013864. doi:\u00a010.1242/jcs.075705. [PubMed] [CrossRef] [Google Scholar]112. Zhou M.H., Lin Y., Zhang Z.G. Intraflagellar transport 20: New target for the treatment of ciliopathies. Biochim. Biophys. Acta Mol. Cell Res. 2020;1867:118641. doi:\u00a010.1016/j.bbamcr.2019.118641. [PubMed] [CrossRef] [Google Scholar]113. Kinzel D., Boldt K., Davis E.E., Burtscher I., Tr\u00fcmbach D., Diplas B., Atti\u00e9-Bitach T., Wurst W., Katsanis N., Ueffing M., et al.  Pitchfork regulates primary cilia disassembly and left-right asymmetry. Dev. Cell. 2010;19:66\u201377. doi:\u00a010.1016/j.devcel.2010.06.005. [PMC free article] [PubMed] [CrossRef] [Google Scholar]114. Nikonova A.S., Deneka A.Y., Kiseleva A.A., Korobeynikov V., Gaponova A., Serebriiskii I.G., Kopp M.C., Hensley H.H., Seeger-Nukpezah T.N., Somlo S., et al.  Ganetespib limits ciliation and cystogenesis in autosomal-dominant polycystic kidney disease (ADPKD) FASEB J. 2018;32:2735\u20132746. doi:\u00a010.1096/fj.201700909R. [PMC free article] [PubMed] [CrossRef] [Google Scholar]115. Sasaki S., Shionoya A., Ishida M., Gambello M.J., Yingling J., Wynshaw-Boris A., Hirotsune S. A LIS1/NUDEL/cytoplasmic dynein heavy chain complex in the developing and adult nervous system. Neuron. 2000;28:681\u2013696. doi:\u00a010.1016/S0896-6273(00)00146-X. [PubMed] [CrossRef] [Google Scholar]116. Niethammer M., Smith D.S., Ayala R., Peng J., Ko J., Lee M.S., Morabito M., Tsai L.H. NUDEL is a novel Cdk5 substrate that associates with LIS1 and cytoplasmic dynein. Neuron. 2000;28:697\u2013711. doi:\u00a010.1016/S0896-6273(00)00147-1. [PubMed] [CrossRef] [Google Scholar]117. Pugacheva E.N., Golemis E.A. The focal adhesion scaffolding protein HEF1 regulates activation of the Aurora-A and Nek2 kinases at the centrosome. Nat. Cell Biol. 2005;7:937\u2013946. doi:\u00a010.1038/ncb1309. [PMC free article] [PubMed] [CrossRef] [Google Scholar]118. Ice R.J., McLaughlin S.L., Livengood R.H., Culp M.V., Eddy E.R., Ivanov A.V., Pugacheva E.N. NEDD9 depletion destabilizes Aurora A kinase and heightens the efficacy of Aurora A inhibitors: Implications for treatment of metastatic solid tumors. Cancer Res. 2013;73:3168\u20133180. doi:\u00a010.1158/0008-5472.CAN-12-4008. [PMC free article] [PubMed] [CrossRef] [Google Scholar]119. Plotnikova O.V., Pugacheva E.N., Dunbrack R.L., Golemis E.A. Rapid calcium-dependent activation of Aurora-A kinase. Nat. Commun. 2010;1:1\u20138. doi:\u00a010.1038/ncomms1061. [PMC free article] [PubMed] [CrossRef] [Google Scholar]120. Ding C., Fan X., Wu G. Peroxiredoxin 1\u2014an antioxidant enzyme in cancer. J. Cell Mol. Med. 2017;21:193\u2013202. doi:\u00a010.1111/jcmm.12955. [PMC free article] [PubMed] [CrossRef] [Google Scholar]121. Ledgerwood E.C., Marshall J.W., Weijman J.F. The role of peroxiredoxin 1 in redox sensing and transducing. Arch. Biochem. Biophys. 2017;617:60\u201367. doi:\u00a010.1016/j.abb.2016.10.009. [PubMed] [CrossRef] [Google Scholar]122. Shagisultanova E., Gaponova A.V., Gabbasov R., Nicolas E., Golemis E.A. Preclinical and clinical studies of the NEDD9 scaffold protein in cancer and other diseases. Gene. 2015;567:1\u201311. doi:\u00a010.1016/j.gene.2015.04.086. [PMC free article] [PubMed] [CrossRef] [Google Scholar]123. Nikonova A.S., Plotnikova O.V., Serzhanova V., Efimov A., Bogush I., Cai K.Q., Hensley H.H., Egleston B.L., Klein-Szanto A., Seeger-Nukpezah T., et al.  Nedd9 restrains renal cystogenesis in Pkd1-/- mice. Proc. Natl. Acad. Sci. USA. 2014;111:12859\u201312864. doi:\u00a010.1073/pnas.1405362111. [PMC free article] [PubMed] [CrossRef] [Google Scholar]124. Riazuddin S.A., Iqbal M., Wang Y., Masuda T., Chen Y., Bowne S., Sullivan L.S., Waseem N.H., Bhattacharya S., Daiger S.P., et al.  A splice-site mutation in a retina-specific exon of BBS8 causes nonsyndromic retinitis pigmentosa. Am. J. Hum. Genet. 2010;86:805\u2013812. doi:\u00a010.1016/j.ajhg.2010.04.001. [PMC free article] [PubMed] [CrossRef] [Google Scholar]125. Goyal S., J\u00e4ger M., Robinson P.N., Vanita V. Confirmation of TTC8 as a disease gene for nonsyndromic autosomal recessive retinitis pigmentosa (RP51) Clin. Genet. 2016;89:454\u2013460. doi:\u00a010.1111/cge.12644. [PubMed] [CrossRef] [Google Scholar]126. May-Simera H.L., Wan Q., Jha B.S., Hartford J., Khristov V., Dejene R., Chang J., Patnaik S., Lu Q., Banerjee P., et al.  Primary cilium-mediated retinal pigment epithelium maturation is disrupted in ciliopathy patient cells. Cell Rep. 2018;22:189\u2013205. doi:\u00a010.1016/j.celrep.2017.12.038. [PMC free article] [PubMed] [CrossRef] [Google Scholar]127. Ansley S.J., Badano J.L., Blacque O.E., Hill J., Hoskins B.E., Leitch C.C., Kim J.C., Ross A.J., Eichers E.R., Teslovich T.M., et al.  Basal body dysfunction is a likely cause of pleiotropic Bardet-Biedl syndrome. Nature. 2003;425:628\u2013633. doi:\u00a010.1038/nature02030. [PubMed] [CrossRef] [Google Scholar]128. Patnaik S.R., Kretschmer V., Br\u00fccker L., Schneider S., Volz A.K., Oancea-Castillo L.D.R., May-Simera H.L. Bardet-Biedl Syndrome proteins regulate cilia disassembly during tissue maturation. Cell. Mol. Life Sci. CMLS. 2019;76:757\u2013775. doi:\u00a010.1007/s00018-018-2966-x. [PubMed] [CrossRef] [Google Scholar]129. Frosk P., Arts H.H., Philippe J., Gunn C.S., Brown E.L., Chodirker B., Simard L., Majewski J., Fahiminiya S., Russell C., et al.  A truncating mutation in CEP55 is the likely cause of MARCH, a novel syndrome affecting neuronal mitosis. J. Med. Genet. 2017;54:490\u2013501. doi:\u00a010.1136/jmedgenet-2016-104296. [PMC free article] [PubMed] [CrossRef] [Google Scholar]130. Bondeson M.L., Ericson K., Gudmundsson S., Ameur A., Pont\u00e9n F., Wesstr\u00f6m J., Frykholm C., Wilbe M. A nonsense mutation in CEP55 defines a new locus for a Meckel-like syndrome, an autosomal recessive lethal fetal ciliopathy. Clin. Genet. 2017;92:510\u2013516. doi:\u00a010.1111/cge.13012. [PubMed] [CrossRef] [Google Scholar]131. Rawlins L.E., Jones H., Wenger O., Aye M., Fasham J., Harlalka G.V., Chioza B.A., Miron A., Ellard S., Wakeling M., et al.  An Amish founder variant consolidates disruption of CEP55 as a cause of hydranencephaly and renal dysplasia. Eur. J. Hum. Genet. 2019;27:657\u2013662. doi:\u00a010.1038/s41431-018-0306-0. [PMC free article] [PubMed] [CrossRef] [Google Scholar]132. Zhang Y.-C., Bai Y.-F., Yuan J.-F., Shen X.-L., Xu Y.-L., Jian X.-X., Li S., Song Z.-Q., Hu H.-B., Li P.-Y., et al.  CEP55 promotes cilia disassembly through stabilizing Aurora A kinase. J. Cell Biol. 2021;220 doi:\u00a010.1083/jcb.202003149. [PMC free article] [PubMed] [CrossRef] [Google Scholar]133. Wang G., Liu M., Wang H., Yu S., Jiang Z., Sun J., Han K., Shen J., Zhu M., Lin Z., et al.  Centrosomal Protein of 55 Regulates Glucose Metabolism, Proliferation and Apoptosis of Glioma Cells via the Akt/mTOR Signaling Pathway. J. Cancer. 2016;7:1431\u20131440. doi:\u00a010.7150/jca.15497. [PMC free article] [PubMed] [CrossRef] [Google Scholar]134. Zhu H., Chen D., Tang J., Huang C., Lv S., Wang D., Li G. Overexpression of centrosomal protein 55 regulates the proliferation of glioma cell and mediates proliferation promoted by EGFRvIII in glioblastoma U251 cells. Oncol. Lett. 2018;15:2700\u20132706. doi:\u00a010.3892/ol.2017.7573. [PMC free article] [PubMed] [CrossRef] [Google Scholar]135. Margaria J.P., Campa C.C., De Santis M.C., Hirsch E., Franco I. The PI3K/Akt/mTOR pathway in polycystic kidney disease: A complex interaction with polycystins and primary cilium. Cell Signal. 2020;66:109468. doi:\u00a010.1016/j.cellsig.2019.109468. [PubMed] [CrossRef] [Google Scholar]136. Manning B.D., Toker A. AKT/PKB Signaling: Navigating the Network. Cell. 2017;169:381\u2013405. doi:\u00a010.1016/j.cell.2017.04.001. [PMC free article] [PubMed] [CrossRef] [Google Scholar]137. Thoma C.R., Frew I.J., Hoerner C.R., Montani M., Moch H., Krek W. pVHL and GSK3beta are components of a primary cilium-maintenance signalling network. Nat. Cell Biol. 2007;9:588\u2013595. doi:\u00a010.1038/ncb1579. [PubMed] [CrossRef] [Google Scholar]138. Beurel E., Grieco S.F., Jope R.S. Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases. Pharm. Ther. 2015;148:114\u2013131. doi:\u00a010.1016/j.pharmthera.2014.11.016. [PMC free article] [PubMed] [CrossRef] [Google Scholar]139. Gao X., Lowry P.R., Zhou X., Depry C., Wei Z., Wong G.W., Zhang J. PI3K/Akt signaling requires spatial compartmentalization in plasma membrane microdomains. Proc. Natl. Acad. Sci. USA. 2011;108:14509\u201314514. doi:\u00a010.1073/pnas.1019386108. [PMC free article] [PubMed] [CrossRef] [Google Scholar]140. Guo J., Otis J.M., Suciu S.K., Catalano C., Xing L., Constable S., Wachten D., Gupton S., Lee J., Lee A., et al.  Primary Cilia Signaling Promotes Axonal Tract Development and Is Disrupted in Joubert Syndrome-Related Disorders Models. Dev. Cell. 2019;51:759\u2013774.e755. doi:\u00a010.1016/j.devcel.2019.11.005. [PMC free article] [PubMed] [CrossRef] [Google Scholar]141. Forcioli-Conti N., Lacas-Gervais S., Dani C., Peraldi P. The primary cilium undergoes dynamic size modifications during adipocyte differentiation of human adipose stem cells. Biochem. Biophys. Res. Commun. 2015;458:117\u2013122. doi:\u00a010.1016/j.bbrc.2015.01.078. [PubMed] [CrossRef] [Google Scholar]142. Engle S.E., Bansal R., Antonellis P.J., Berbari N.F. Cilia signaling and obesity. Semin. Cell Dev. Biol. 2020 doi:\u00a010.1016/j.semcdb.2020.05.006. [PMC free article] [PubMed] [CrossRef] [Google Scholar]143. Zhu D., Shi S., Wang H., Liao K. Growth arrest induces primary-cilium formation and sensitizes IGF-1-receptor signaling during differentiation induction of 3T3-L1 preadipocytes. J. Cell Sci. 2009;122:2760\u20132768. doi:\u00a010.1242/jcs.046276. [PubMed] [CrossRef] [Google Scholar]144. Dalbay M.T., Thorpe S.D., Connelly J.T., Chapple J.P., Knight M.M. Adipogenic Differentiation of hMSCs is Mediated by Recruitment of IGF-1r Onto the Primary Cilium Associated With Cilia Elongation. Stem Cells. 2015;33:1952\u20131961. doi:\u00a010.1002/stem.1975. [PMC free article] [PubMed] [CrossRef] [Google Scholar]145. Haczeyni F., Bell-Anderson K.S., Farrell G.C. Causes and mechanisms of adipocyte enlargement and adipose expansion. Obes. Rev. 2018;19:406\u2013420. doi:\u00a010.1111/obr.12646. [PubMed] [CrossRef] [Google Scholar]146. Kopinke D., Roberson E.C., Reiter J.F. Ciliary Hedgehog Signaling Restricts Injury-Induced Adipogenesis. Cell. 2017;170:340\u2013351. doi:\u00a010.1016/j.cell.2017.06.035. [PMC free article] [PubMed] [CrossRef] [Google Scholar]147. Huo H., Guo X., Hong S., Jiang M., Liu X., Liao K. Lipid rafts/caveolae are essential for insulin-like growth factor-1 receptor signaling during 3T3-L1 preadipocyte differentiation induction. J. Biol. Chem. 2003;278:11561\u201311569. doi:\u00a010.1074/jbc.M211785200. [PubMed] [CrossRef] [Google Scholar]148. S\u00e1nchez-Wandelmer J., D\u00e1valos A., Herrera E., Giera M., Cano S., de la Pe\u00f1a G., Lasunci\u00f3n M.A., Busto R. Inhibition of cholesterol biosynthesis disrupts lipid raft/caveolae and affects insulin receptor activation in 3T3-L1 preadipocytes. Biochim. Et Biophys. Acta. 2009;1788:1731\u20131739. doi:\u00a010.1016/j.bbamem.2009.05.002. [PubMed] [CrossRef] [Google Scholar]149. Levental I., Levental K.R., Heberle F.A. Lipid Rafts: Controversies Resolved, Mysteries Remain. Trends Cell Biol. 2020;30:341\u2013353. doi:\u00a010.1016/j.tcb.2020.01.009. [PMC free article] [PubMed] [CrossRef] [Google Scholar]150. Sezgin E., Levental I., Mayor S., Eggeling C. The mystery of membrane organization: Composition, regulation and roles of lipid rafts. Nat. Rev. Mol. Cell Biol. 2017;18:361\u2013374. doi:\u00a010.1038/nrm.2017.16. [PMC free article] [PubMed] [CrossRef] [Google Scholar]151. Van Deventer S., Arp A.B., van Spriel A.B. Dynamic Plasma Membrane Organization: A Complex Symphony. Trends Cell Biol. 2021;31:119\u2013129. doi:\u00a010.1016/j.tcb.2020.11.004. [PubMed] [CrossRef] [Google Scholar]152. Pike L.J. Rafts defined: A report on the Keystone Symposium on Lipid Rafts and Cell Function. J. Lipid Res. 2006;47:1597\u20131598. doi:\u00a010.1194/jlr.E600002-JLR200. [PubMed] [CrossRef] [Google Scholar]153. Simons K., Sampaio J.L. Membrane organization and lipid rafts. Cold Spring Harb. Perspect. Biol. 2011;3:a004697. doi:\u00a010.1101/cshperspect.a004697. [PMC free article] [PubMed] [CrossRef] [Google Scholar]154. Hryniewicz-Jankowska A., Augoff K., Sikorski A.F. The role of cholesterol and cholesterol-driven membrane raft domains in prostate cancer. Exp. Biol. Med. 2019;244:1053\u20131061. doi:\u00a010.1177/1535370219870771. [PMC free article] [PubMed] [CrossRef] [Google Scholar]155. Greenlee J.D., Subramanian T., Liu K., King M.R. Rafting Down the Metastatic Cascade: The Role of Lipid Rafts in Cancer Metastasis, Cell Death, and Clinical Outcomes. Cancer Res. 2021;81:5. doi:\u00a010.1158/0008-5472.CAN-20-2199. [PMC free article] [PubMed] [CrossRef] [Google Scholar]156. Beloribi-Djefaflia S., Vasseur S., Guillaumond F. Lipid metabolic reprogramming in cancer cells. Oncogenesis. 2016;5:e189. doi:\u00a010.1038/oncsis.2015.49. [PMC free article] [PubMed] [CrossRef] [Google Scholar]157. Pike L.J. Growth factor receptors, lipid rafts and caveolae: An evolving story. Biochim. Biophys. Acta. 2005;1746:260\u2013273. doi:\u00a010.1016/j.bbamcr.2005.05.005. [PubMed] [CrossRef] [Google Scholar]158. Delos Santos R.C., Garay C., Antonescu C.N. Charming neighborhoods on the cell surface: Plasma membrane microdomains regulate receptor tyrosine kinase signaling. Cell. Signal. 2015;27:1963\u20131976. doi:\u00a010.1016/j.cellsig.2015.07.004. [PubMed] [CrossRef] [Google Scholar]159. Julien S., Bobowski M., Steenackers A., Le Bourhis X., Delannoy P. How Do Gangliosides Regulate RTKs Signaling? Cells. 2013;2:751\u2013767. doi:\u00a010.3390/cells2040751. [PMC free article] [PubMed] [CrossRef] [Google Scholar]160. Lu S.M., Fairn G.D. Mesoscale organization of domains in the plasma membrane\u2014Beyond the lipid raft. Crit. Rev. Biochem. Mol. Biol. 2018;53:192\u2013207. doi:\u00a010.1080/10409238.2018.1436515. [PubMed] [CrossRef] [Google Scholar]161. Mollinedo F., Gajate C. Lipid rafts as major platforms for signaling regulation in cancer. Adv. Biol. Regul. 2015;57:130\u2013146. doi:\u00a010.1016/j.jbior.2014.10.003. [PubMed] [CrossRef] [Google Scholar]162. Mollinedo F., Gajate C. Lipid rafts as signaling hubs in cancer cell survival/death and invasion: Implications in tumor progression and therapy. J. Lipid. Res. 2020;61:611\u2013635. doi:\u00a010.1194/jlr.TR119000439. [PMC free article] [PubMed] [CrossRef] [Google Scholar]163. Nishimura Y., Yamakawa D., Uchida K., Shiromizu T., Watanabe M., Inagaki M. Primary cilia and lipid raft dynamics. Open Biol. 2021;11:210130. doi:\u00a010.1098/rsob.210130. [PMC free article] [PubMed] [CrossRef] [Google Scholar]164. Veland I.R., Awan A., Pedersen L.B., Yoder B.K., Christensen S.T. Primary cilia and signaling pathways in mammalian development, health and disease. Nephron. Physiol. 2009;111:39\u201353. doi:\u00a010.1159/000208212. [PMC free article] [PubMed] [CrossRef] [Google Scholar]165. Stahlhut M., van Deurs B. Identification of filamin as a novel ligand for caveolin-1: Evidence for the organization of caveolin-1-associated membrane domains by the actin cytoskeleton. Mol. Biol. Cell. 2000;11:325\u2013337. doi:\u00a010.1091/mbc.11.1.325. [PMC free article] [PubMed] [CrossRef] [Google Scholar]166. Echarri A., Del Pozo M.A. Caveolae\u2014mechanosensitive membrane invaginations linked to actin filaments. J. Cell Sci. 2015;128:2747. doi:\u00a010.1242/jcs.153940. [PubMed] [CrossRef] [Google Scholar]167. Matthaeus C., Taraska J.W. Energy and Dynamics of Caveolae Trafficking. Front. Cell Dev. Biol. 2021;8:614472. doi:\u00a010.3389/fcell.2020.614472. [PMC free article] [PubMed] [CrossRef] [Google Scholar]168. Sviridov D., Mukhamedova N., Miller Y.I. Lipid rafts as a therapeutic target. J. Lipid. Res. 2020;61:687\u2013695. doi:\u00a010.1194/jlr.TR120000658. [PMC free article] [PubMed] [CrossRef] [Google Scholar]169. Miller Y.I., Navia-Pelaez J.M., Corr M., Yaksh T.L. Lipid rafts in glial cells: Role in neuroinflammation and pain processing. J. Lipid. Res. 2020;61:655\u2013666. doi:\u00a010.1194/jlr.TR119000468. [PMC free article] [PubMed] [CrossRef] [Google Scholar]170. Vona R., Iessi E., Matarrese P. Role of Cholesterol and Lipid Rafts in Cancer Signaling: A Promising Therapeutic Opportunity? Front. Cell Dev. Biol. 2021;9:622908. doi:\u00a010.3389/fcell.2021.622908. [PMC free article] [PubMed] [CrossRef] [Google Scholar]171. Choudhury A., Neumann N.M., Raleigh D.R., Lang U.E. Clinical Implications of Primary Cilia in Skin Cancer. Dermatol. Ther. 2020;10:233\u2013248. doi:\u00a010.1007/s13555-020-00355-1. [PMC free article] [PubMed] [CrossRef] [Google Scholar]172. Coelho P.A., Bury L., Shahbazi M.N., Liakath-Ali K., Tate P.H., Wormald S., Hindley C.J., Huch M., Archer J., Skarnes W.C., et al.  Over-expression of Plk4 induces centrosome amplification, loss of primary cilia and associated tissue hyperplasia in the mouse. Open Biol. 2015;5:150209. doi:\u00a010.1098/rsob.150209. [PMC free article] [PubMed] [CrossRef] [Google Scholar]173. Dufour J., Viennois E., De Boussac H., Baron S., Lobaccaro J.M. Oxysterol receptors, AKT and prostate cancer. Curr. Opin. Pharm. 2012;12:724\u2013728. doi:\u00a010.1016/j.coph.2012.06.012. [PubMed] [CrossRef] [Google Scholar]174. Nechipurenko I.V. The Enigmatic Role of Lipids in Cilia Signaling. Front. Cell Dev. Biol. 2020;8:777. doi:\u00a010.3389/fcell.2020.00777. [PMC free article] [PubMed] [CrossRef] [Google Scholar]175. Eramo M.J., Mitchell C.A. Regulation of PtdIns(3,4,5)P3/Akt signalling by inositol polyphosphate 5-phosphatases. Biochem. Soc. Trans. 2016;44:240\u2013252. doi:\u00a010.1042/BST20150214. [PubMed] [CrossRef] [Google Scholar]176. Bielas S.L., Silhavy J.L., Brancati F., Kisseleva M.V., Al-Gazali L., Sztriha L., Bayoumi R.A., Zaki M.S., Abdel-Aleem A., Rosti R.O., et al.  Mutations in INPP5E, encoding inositol polyphosphate-5-phosphatase E, link phosphatidyl inositol signaling to the ciliopathies. Nat. Genet. 2009;41:1032\u20131036. doi:\u00a010.1038/ng.423. [PMC free article] [PubMed] [CrossRef] [Google Scholar]177. Hakim S., Dyson J.M., Feeney S.J., Davies E.M., Sriratana A., Koenig M.N., Plotnikova O.V., Smyth I.M., Ricardo S.D., Hobbs R.M., et al.  Inpp5e suppresses polycystic kidney disease via inhibition of PI3K/Akt-dependent mTORC1 signaling. Hum. Mol. Genet. 2016;25:2295\u20132313. doi:\u00a010.1093/hmg/ddw097. [PubMed] [CrossRef] [Google Scholar]178. Xu W., Jin M., Hu R., Wang H., Zhang F., Yuan S., Cao Y. The Joubert Syndrome Protein Inpp5e Controls Ciliogenesis by Regulating Phosphoinositides at the Apical Membrane. J. Am. Soc. Nephrol. 2017;28:118\u2013129. doi:\u00a010.1681/ASN.2015080906. [PMC free article] [PubMed] [CrossRef] [Google Scholar]179. Sierra Potchanant E.A., Cerabona D., Sater Z.A., He Y., Sun Z., Gehlhausen J., Nalepa G. INPP5E Preserves Genomic Stability through Regulation of Mitosis. Mol. Cell. Biol. 2017;37 doi:\u00a010.1128/MCB.00500-16. [PMC free article] [PubMed] [CrossRef] [Google Scholar]180. Ivan M., Kondo K., Yang H., Kim W., Valiando J., Ohh M., Salic A., Asara J.M., Lane W.S., Kaelin W.G.J. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science. 2001;292:464\u2013468. doi:\u00a010.1126/science.1059817. [PubMed] [CrossRef] [Google Scholar]181. Epstein A.C., Gleadle J.M., McNeill L.A., Hewitson K.S., O\u2019Rourke J., Mole D.R., Mukherji M., Metzen E., Wilson M.I., Dhanda A., et al.  C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001;107:43\u201354. doi:\u00a010.1016/S0092-8674(01)00507-4. [PubMed] [CrossRef] [Google Scholar]182. Hon W.C., Wilson M.I., Harlos K., Claridge T.D., Schofield C.J., Pugh C.W., Maxwell P.H., Ratcliffe P.J., Stuart D.I., Jones E.Y. Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. Nature. 2002;417:975\u2013978. doi:\u00a010.1038/nature00767. [PubMed] [CrossRef] [Google Scholar]183. Gossage L., Eisen T., Maher E.R. VHL, the story of a tumour suppressor gene. Nat. Rev. Cancer. 2015;15:55\u201364. doi:\u00a010.1038/nrc3844. [PubMed] [CrossRef] [Google Scholar]184. Chittiboina P., Lonser R.R. Von Hippel-Lindau disease. Handb. Clin. Neurol. 2015;132:139\u2013156. doi:\u00a010.1016/b978-0-444-62702-5.00010-x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]185. Lutz M.S., Burk R.D. Primary cilium formation requires von hippel-lindau gene function in renal-derived cells. Cancer Res. 2006;66:6903\u20136907. doi:\u00a010.1158/0008-5472.CAN-06-0501. [PubMed] [CrossRef] [Google Scholar]186. Guo J., Chakraborty A.A., Liu P., Gan W., Zheng X., Inuzuka H., Wang B., Zhang J., Zhang L., Yuan M., et al.  pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner. Science. 2016;353:929\u2013932. doi:\u00a010.1126/science.aad5755. [PMC free article] [PubMed] [CrossRef] [Google Scholar]187. Minervini G., Pennuto M., Tosatto S.C.E. The pVHL neglected functions, a tale of hypoxia-dependent and -independent regulations in cancer. Open Biol. 2020;10:200109. doi:\u00a010.1098/rsob.200109. [PMC free article] [PubMed] [CrossRef] [Google Scholar]188. Chowdhury P., Perera D., Powell R.T., Talley T., Tripathi D.N., Park Y.S., Mancini M.A., Davies P., Stephan C., Corfa C., et al.  Therapeutically actionable signaling node to rescue AURKA driven loss of primary cilia in VHL-deficient cells. Sci. Rep. 2021;11:10461. doi:\u00a010.1038/s41598-021-89933-7. [PMC free article] [PubMed] [CrossRef] [Google Scholar]189. Sato Y., Yoshizato T., Shiraishi Y., Maekawa S., Okuno Y., Kamura T., Shimamura T., Sato-Otsubo A., Nagae G., Suzuki H., et al.  Integrated molecular analysis of clear-cell renal cell carcinoma. Nat. Genet. 2013;45:860\u2013867. doi:\u00a010.1038/ng.2699. [PubMed] [CrossRef] [Google Scholar]190. Gerlinger M., Horswell S., Larkin J., Rowan A.J., Salm M.P., Varela I., Fisher R., McGranahan N., Matthews N., Santos C.R., et al.  Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 2014;46:225\u2013233. doi:\u00a010.1038/ng.2891. [PMC free article] [PubMed] [CrossRef] [Google Scholar]191. Hou W., Ji Z. Generation of autochthonous mouse models of clear cell renal cell carcinoma: Mouse models of renal cell carcinoma. Exp. Mol. Med. 2018;50:1\u201310. doi:\u00a010.1038/s12276-018-0059-4. [PMC free article] [PubMed] [CrossRef] [Google Scholar]192. Guo H., German P., Bai S., Barnes S., Guo W., Qi X., Lou H., Liang J., Jonasch E., Mills G.B., et al.  The PI3K/AKT Pathway and Renal Cell Carcinoma. J. Genet. Genom. 2015;42:343\u2013353. doi:\u00a010.1016/j.jgg.2015.03.003. [PMC free article] [PubMed] [CrossRef] [Google Scholar]193. Cohen P., Cross D., J\u00e4nne P.A. Kinase drug discovery 20 years after imatinib: Progress and future directions. Nat. Rev. Drug Discov. 2021;20:551\u2013569. doi:\u00a010.1038/s41573-021-00195-4. [PMC free article] [PubMed] [CrossRef] [Google Scholar]194. McIntyre P.J., Collins P.M., Vrzal L., Birchall K., Arnold L.H., Mpamhanga C., Coombs P.J., Burgess S.G., Richards M.W., Winter A., et al.  Characterization of Three Druggable Hot-Spots in the Aurora-A/TPX2 Interaction Using Biochemical, Biophysical, and Fragment-Based Approaches. ACS Chem. Biol. 2017;12:2906\u20132914. doi:\u00a010.1021/acschembio.7b00537. [PubMed] [CrossRef] [Google Scholar]195. Narvaez A.J., Ber S., Crooks A., Emery A., Hardwick B., Guarino Almeida E., Huggins D.J., Perera D., Roberts-Thomson M., Azzarelli R., et al.  Modulating Protein-Protein Interactions of the Mitotic Polo-like Kinases to Target Mutant KRAS. Cell Chem. Biol. 2017;24:1017\u20131028.e1017. doi:\u00a010.1016/j.chembiol.2017.07.009. [PMC free article] [PubMed] [CrossRef] [Google Scholar]196. Ran X., Gestwicki J.E. Inhibitors of protein\u2013protein interactions (PPIs): An analysis of scaffold choices and buried surface area. Curr. Opin. Chem. Biol. 2018;44:75\u201386. doi:\u00a010.1016/j.cbpa.2018.06.004. [PMC free article] [PubMed] [CrossRef] [Google Scholar]197. Kufer T.A., Sillj\u00e9 H.H., K\u00f6rner R., Gruss O.J., Meraldi P., Nigg E.A. Human TPX2 is required for targeting Aurora-A kinase to the spindle. J. Cell Biol. 2002;158:617\u2013623. doi:\u00a010.1083/jcb.200204155. [PMC free article] [PubMed] [CrossRef] [Google Scholar]198. Bird A.W., Hyman A.A. Building a spindle of the correct length in human cells requires the interaction between TPX2 and Aurora A. J. Cell Biol. 2008;182:289\u2013300. doi:\u00a010.1083/jcb.200802005. [PMC free article] [PubMed] [CrossRef] [Google Scholar]199. Gupta P., Mohanty D. SMMPPI: A machine learning-based approach for prediction of modulators of protein-protein interactions and its application for identification of novel inhibitors for RBD:hACE2 interactions in SARS-CoV-2. Brief. Bioinform. 2021;22 doi:\u00a010.1093/bib/bbab111. [PMC free article] [PubMed] [CrossRef] [Google Scholar]200. Choi J., Yun J.S., Song H., Kim N.H., Kim H.S., Yook J.I. Exploring the chemical space of protein\u2013protein interaction inhibitors through machine learning. Sci. Rep. 2021;11:13369. doi:\u00a010.1038/s41598-021-92825-5. [PMC free article] [PubMed] [CrossRef] [Google Scholar]201. Lu H., Zhou Q., He J., Jiang Z., Peng C., Tong R., Shi J. Recent advances in the development of protein\u2013protein interactions modulators: Mechanisms and clinical trials. Signal Transduct. Target. Ther. 2020;5:213. doi:\u00a010.1038/s41392-020-00315-3. [PMC free article] [PubMed] [CrossRef] [Google Scholar]202. Lai A.C., Crews C.M. Induced protein degradation: An emerging drug discovery paradigm. Nat. Rev. Drug Discov. 2017;16:101\u2013114. doi:\u00a010.1038/nrd.2016.211. [PMC free article] [PubMed] [CrossRef] [Google Scholar]203. Naito M., Ohoka N., Shibata N. SNIPERs-Hijacking IAP activity to induce protein degradation. Drug Discov. Today Technol. 2019;31:35\u201342. doi:\u00a010.1016/j.ddtec.2018.12.002. [PubMed] [CrossRef] [Google Scholar]204. He M., Lv W., Rao Y. Opportunities and Challenges of Small Molecule Induced Targeted Protein Degradation. Front. Cell Dev. Biol. 2021;9 doi:\u00a010.3389/fcell.2021.685106. [PMC free article] [PubMed] [CrossRef] [Google Scholar]205. Agnew H.D., Coppock M.B., Idso M.N., Lai B.T., Liang J., McCarthy-Torrens A.M., Warren C.M., Heath J.R. Protein-Catalyzed Capture Agents. Chem. Rev. 2019;119:9950\u20139970. doi:\u00a010.1021/acs.chemrev.8b00660. [PMC free article] [PubMed] [CrossRef] [Google Scholar]206. Wang Y., Jiang X., Feng F., Liu W., Sun H. Degradation of proteins by PROTACs and other strategies. Acta Pharm. Sin. B. 2020;10:207\u2013238. doi:\u00a010.1016/j.apsb.2019.08.001. [PMC free article] [PubMed] [CrossRef] [Google Scholar]207. Sells T.B., Chau R., Ecsedy J.A., Gershman R.E., Hoar K., Huck J., Janowick D.A., Kadambi V.J., LeRoy P.J., Stirling M., et al.  MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors. ACS Med. Chem. Lett. 2015;6:630\u2013634. doi:\u00a010.1021/ml500409n. [PMC free article] [PubMed] [CrossRef] [Google Scholar]208. You I., Erickson E.C., Donovan K.A., Eleuteri N.A., Fischer E.S., Gray N.S., Toker A. Discovery of an AKT Degrader with Prolonged Inhibition of Downstream Signaling. Cell Chem. Biol. 2020;27:66\u201373.e67. doi:\u00a010.1016/j.chembiol.2019.11.014. [PMC free article] [PubMed] [CrossRef] [Google Scholar]209. Henning R.K., Varghese J.O., Das S., Nag A., Tang G., Tang K., Sutherland A.M., Heath J.R. Degradation of Akt using protein-catalyzed capture agents. J. Pept. Sci. 2016;22:196\u2013200. doi:\u00a010.1002/psc.2858. [PMC free article] [PubMed] [CrossRef] [Google Scholar]210. Br\u00e8s V., Yoh S.M., Jones K.A. The multi-tasking P-TEFb complex. Curr. Opin. Cell Biol. 2008;20:334\u2013340. doi:\u00a010.1016/j.ceb.2008.04.008. [PMC free article] [PubMed] [CrossRef] [Google Scholar]211. Bechter O., Sch\u00f6ffski P. Make your best BET: The emerging role of BET inhibitor treatment in malignant tumors. Pharmacol. Ther. 2020;208:107479. doi:\u00a010.1016/j.pharmthera.2020.107479. [PubMed] [CrossRef] [Google Scholar]212. Lim S.L., Xu L., Han B.C., Shyamsunder P., Chng W.J., Koeffler H.P. Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor. PLoS ONE. 2020;15:e0232068.  doi:\u00a010.1371/journal.pone.0232068. [PMC free article] [PubMed] [CrossRef] [Google Scholar]213. Qi S.-M., Dong J., Xu Z.-Y., Cheng X.-D., Zhang W.-D., Qin J.-J. PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy. Front. Pharmacol. 2021;12 doi:\u00a010.3389/fphar.2021.692574. [PMC free article] [PubMed] [CrossRef] [Google Scholar]214. Bertolin G., Sizaire F., Herbomel G., Reboutier D., Prigent C., Tramier M. A FRET biosensor reveals spatiotemporal activation and functions of aurora kinase A in living cells. Nat. Commun. 2016;7:12674. doi:\u00a010.1038/ncomms12674. [PMC free article] [PubMed] [CrossRef] [Google Scholar]215. Miura H., Matsuda M., Aoki K. Development of a FRET Biosensor with High Specificity for Akt. Cell Struct. Funct. 2014;39:9\u201320. doi:\u00a010.1247/csf.13018. [PubMed] [CrossRef] [Google Scholar]216. Agarwal S.R., Gratwohl J., Cozad M., Yang P.C., Clancy C.E., Harvey R.D. Compartmentalized cAMP Signaling Associated With Lipid Raft and Non-raft Membrane Domains in Adult Ventricular Myocytes. Front. Pharmacol. 2018;9:332. doi:\u00a010.3389/fphar.2018.00332. [PMC free article] [PubMed] [CrossRef] [Google Scholar]217. Jiang J.Y., Falcone J.L., Curci S., Hofer A.M. Direct visualization of cAMP signaling in primary cilia reveals up-regulation of ciliary GPCR activity following Hedgehog activation. Proc. Natl. Acad. Sci. USA. 2019;116:12066\u201312071. doi:\u00a010.1073/pnas.1819730116. [PMC free article] [PubMed] [CrossRef] [Google Scholar]218. Lee K.L., Guevarra M.D., Nguyen A.M., Chua M.C., Wang Y., Jacobs C.R. The primary cilium functions as a mechanical and calcium signaling nexus. Cilia. 2015;4:7. doi:\u00a010.1186/s13630-015-0016-y. [PMC free article] [PubMed] [CrossRef] [Google Scholar]219. Ni Q., Titov D.V., Zhang J. Analyzing protein kinase dynamics in living cells with FRET reporters. Methods. 2006;40:279\u2013286. doi:\u00a010.1016/j.ymeth.2006.06.013. [PubMed] [CrossRef] [Google Scholar]220. Mukherjee S., Jansen V., Jikeli J.F., Hamzeh H., Alvarez L., Dombrowski M., Balbach M., Str\u00fcnker T., Seifert R., Kaupp U.B., et al.  A novel biosensor to study cAMP dynamics in cilia and flagella. eLife. 2016;5:e14052. doi:\u00a010.7554/eLife.14052. [PMC free article] [PubMed] [CrossRef] [Google Scholar]221. Arslanhan M.D., Gulensoy D., Firat-Karalar E.N. A Proximity Mapping Journey into the Biology of the Mammalian Centrosome/Cilium Complex. Cells. 2020;9:1390.  doi:\u00a010.3390/cells9061390. [PMC free article] [PubMed] [CrossRef] [Google Scholar]222. Devi R., Pelletier L., Prosser S.L. Charting the complex composite nature of centrosomes, primary cilia and centriolar satellites. Curr. Opin. Struct. Biol. 2021;66:32\u201340. doi:\u00a010.1016/j.sbi.2020.10.006. [PubMed] [CrossRef] [Google Scholar]223. Kim S., Carruthers N., Lee J., Chinni S., Stemmer P. Classification-based quantitative analysis of stable isotope labeling by amino acids in cell culture (SILAC) data. Comput. Methods Programs Biomed. 2016;137:137\u2013148. doi:\u00a010.1016/j.cmpb.2016.09.017. [PMC free article] [PubMed] [CrossRef] [Google Scholar]224. Duggal S., Jailkhani N., Midha M.K., Agrawal N., Rao K.V.S., Kumar A. Defining the Akt1 interactome and its role in regulating the cell cycle. Sci. Rep. 2018;8:1303. doi:\u00a010.1038/s41598-018-19689-0. [PMC free article] [PubMed] [CrossRef] [Google Scholar]"}